

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/12, 15/85, A61K 39/395, C07K 14/48		(11) International Publication Number: WO 97/16548
A1		(43) International Publication Date: 9 May 1997 (09.05.97)
(21) International Application Number: PCT/US96/17532		(US). HOLLENBERG, Stanley, M. [US/US]; 6413 S.W. Roundtree Court, Portland, OR 97219 (US). TAPSCOTT, Stephen, J. [US/US]; 3419 S. Dose Terrace, Seattle, WA 98144 (US).
(22) International Filing Date: 30 October 1996 (30.10.96)		(74) Agent: SHEINESS, Diana, K.; Christensen O'Connor Johnson & Kindness P.L.L.C., Suite 2800, 1420 Fifth Avenue, Seattle, WA 98101 (US).
(30) Priority Data: 08/552,142 2 November 1995 (02.11.95) US		(81) Designated States: CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(60) Parent Application or Grant (63) Related by Continuation US 08/552,142 (CIP) Filed on 2 November 1995 (02.11.95)		Published With international search report.
(71) Applicant (for all designated States except US): FRED HUTCHINSON CANCER RESEARCH CENTER [US/US]; 1124 Columbia Street, Seattle, WA 98104 (US).		
(71) Applicant (for US only): WEINTRAUB, Nancy (executrix for the deceased inventor) [US/US]; 1223 - 16th Avenue E., Seattle, WA 98112 (US).		
(72) Inventor: WEINTRAUB, Harold, M. (deceased).		
(72) Inventors; and (75) Inventors/Applicants (for US only): LEE, Jacqueline, E. [US/US]; 922 S. Ogden, Denver, CO 80209-4426		
(54) Title: NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS		
(57) Abstract <p>Neurogenic differentiation genes and proteins from human, mouse, and frog are identified, isolated, and sequenced. Expression of <i>neuroD1</i> has been demonstrated in neural, pancreatic, and gastrointestinal cells, and expression of <i>neuroD2</i> was detected in brain. Ectopic expression of <i>neuroD1</i> and <i>neuroD2</i> in non-neuronal cells of <i>Xenopus</i> embryos induced formation of neurons. <i>NeuroD1</i> knock-out mice had diabetes.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

NEUROGENIC DIFFERENTIATION (NeuroD) GENES AND PROTEINS

This invention was made with government support under grant CA42506 awarded by the National Institutes of Health. The government has certain rights in the invention.

5 This application is a continuation-in-part of co-pending U.S. application No. 08/552,142, filed November 2, 1995, which is a continuation-in-part of PCT application No. PCT/US95/05741, which is a continuation-in-part of parent application U.S. Serial No. 08/239,238, filed May 6, 1994 (abandoned).

Field of the Invention

10 The invention relates to molecular biology and in particular to genes and proteins involved in vertebrate neural development.

Background of the Invention

Transcription factors of the basic-helix-loop-helix (bHLH) family are implicated in the regulation of differentiation in a wide variety of cell types, including
15 trophoblast cells (Cross et al., *Development* 121:2513-2523, 1995), pigment cells (Steingrimsson et al., *Nature Gen.* 8:251-255, 1994), B-cells (Shen, C.P. and T. Kadesch., *Molec. & Cell. Biol.* 15:3813-3822, 1995; Zhuang et al., *Cell* 79:875-884, 1994), chondrocytes and osteoblasts (Cserjesi et al., *Development* 121:1099-1110, 1995; Tamura, M. and M. Noda., *J. Cell Biol.* 126:773-782, 1994), and cardiac
20 muscle (Burgess et al., *Develop. Biol.* 168:296-306, 1995; Hollenberg et al., *Molec. & Cell. Biol.* 15:3813-3822, 1995). bHLH proteins form homodimeric and

heterodimeric complexes that bind with DNA in the 5' regulatory regions of genes controlling expression.

Perhaps the most extensively studied sub-families of bHLH proteins are those that regulate myogenesis and neurogenesis. The myogenic bHLH factors, (MyoD, myogenin, Myf5, and MRF4), appear to have unique as well as redundant functions during myogenesis (Weintraub, H., *Cell* 75:1241-1244, 1993; Weintraub et al., *Science* 251:761-766, 1991). It is thought that either Myf5 or MyoD is necessary to determine myogenic fate, whereas myogenin is necessary for events involved in terminal differentiation (Hasty et al., *Nature* 364:501-506, 1993; Nabeshima et al., *Nature* 364:532-535, 1993; Rudnicki et al., *Cell* 75:1351-1359, 1993; Venuti et al., *J. Cell Biol.* 128:563-576, 1995). Recent work on neurogenic bHLH proteins suggests parallels between the myogenic and neurogenic sub-families of bHLH proteins. Genes of the *Drosophila melanogaster achaete-scute* complex and the *atonal* gene have been shown to be involved in neural cell fate determination (Anderson, D. J., *Cur. Biol.* 5:1235-1238, 1995; Campuzano, S. and J. Modolell., *Trends in Genetics* 8:202-208, 1992; Jaman et al., *Cell* 73:1307-1321, 1993), and the mammalian homologs, *MASH1* and *MATH1*, are expressed in the neural tube at the time of neurogenesis (Akazawa et al., *J. Biol. Chem.* 270:8730-8738, 1995; Lo et al., *Genes & Dev.* 5:1524-1537, 1991). Two related vertebrate bHLH proteins, neuroD (hereafter referred to as "neuroD1") and NEX-1/MATH-2, are expressed slightly later in CNS development, predominantly in the marginal layer of the neural tube and persisting in the mature nervous system (Bartholoma, A. and K. A. Nave., *Mech. Dev.* 48:217-228, 1994; Lee et al., *Science* 268:836-844, 1995; Shimizu et al., *Eur. J. Biochem.* 229:239-248, 1995). NeuroD1 was also cloned as a factor that regulates insulin transcription in pancreatic beta cells and named "Beta2" (Naya et al., *Genes & Dev.* 9:1009-1019, 1995). Constitutive expression of neuroD1 in developing *Xenopus* embryos produces ectopic neurogenesis in the ectodermal cells, indicating that neuroD is capable of regulating a neurogenic program. A neuroD1 homolog having 36,873 nucleotides has been identified in *C. elegans* (Lee et al., 1995; Genbank Accession No. 010402), suggesting that this molecular mechanism of regulating neurogenesis may be conserved between vertebrates and invertebrates.

Neural tissues and endocrine tissues do not regenerate. Damage is permanent. Paralysis, loss of vision or hearing, and hormonal insufficiency are also intractable medical conditions. Furthermore, tumors in neural and endocrine tissues can be very difficult to treat because of the toxic side effects that conventional chemotherapeutic

drugs may have on nervous tissues. The medical community and public would greatly benefit from the availability of agents active in triggering differentiation in neuroectodermal stem cells. Such neuronal differentiating agents could be used for construction of test cell lines, assays for identifying candidate therapeutic agents capable of inducing regeneration of neuronal and endocrine tissues, gene therapy, and differentiation of tumor cells.

Summary of the Invention

The presently disclosed neuroD proteins represent a new sub-family of bHLH proteins and are implicated in vertebrate neuronal, endocrine and gastrointestinal development. Mammalian and amphibian neuroD proteins were identified, and polynucleotide molecules encoding neuroD proteins were isolated and sequenced. *NeuroD* genes encode proteins that are distinctive members of the bHLH family. In addition, the present invention provides a family of neuroD proteins that share a highly conserved HLH region. Representative polynucleotide molecules encoding members of the neuroD family include *neuroD1*, *neuroD2* and *neuroD3*.

A representative nucleotide sequence encoding murine neuroD1 is shown in SEQ ID NO:1. The HLH coding domain of murine neuroD1 resides between nucleotides 577 and 696 in SEQ ID NO:1. The deduced amino acid sequence of murine neuroD1 is shown in SEQ ID NO:2. There is a highly conserved region following the helix-2 domain from amino acid 150 through amino acid 199 of SEQ ID NO:2 that is not shared by other bHLH proteins.

A representative nucleotide sequence encoding *Xenopus neuroD1* is shown in SEQ ID NO:3. The HLH coding domain of *Xenopus neuroD1* resides between nucleotides 376 and 495 in SEQ ID NO:3. The deduced amino acid sequence of *Xenopus neuroD1* is shown in SEQ ID NO:4. There is a highly conserved region following the helix-2 domain from amino acid 157 through amino acid 199 of SEQ ID NO:4 that is not shared by other bHLH proteins.

Representative nucleotide and deduced amino acid sequences of the human neuroD family are shown in SEQ ID NOS:8-15. Representative nucleotide and deduced amino acid sequences of a human homolog of murine neuroD1 are shown in SEQ ID NOS:8 and 9 (partial genomic sequence) and SEQ ID NOS:14 and 15 (human *neuroD1* cDNA). Representative nucleotide and deduced amino acid sequences of the human and murine *neuroD2* are shown in SEQ ID NOS:10 and 11, and 16 and 17, respectively. Representative nucleotide and deduced amino acid sequences for human *neuroD3* are shown in SEQ ID NOS:12 and 13. The disclosed

human clones, 9F1 (and its corresponding cDNA HC2A; now referred to as human *neuroD1*) and 14B1 (now referred to as human *neuroD2*), have an identical HLH motif: Amino acid residues 117-156 in SEQ ID NO:9 and 15, and residues 137-176 in SEQ ID NO:11 (corresponding to nucleotides 405-524 of SEQ ID NO:8 and SEQ ID NO:14, and nucleotides 463-582 of SEQ ID NO:10). Comparison of the deduced amino acid sequences of these *neuroD* genes shows that human *neuroD3* contains an HLH domain between amino acid residues 108-147 of SEQ ID NO:13 (corresponding to nucleotides 376-495 of SEQ ID NO:12) and that murine *neuroD2* contains an HLH domain between amino acids residues 138-177 of SEQ ID NO:17 (corresponding to nucleotides 641-760 of SEQ ID NO:16). The HLH domain of murine *neuroD2* is identical to that of the human *neuroD1* and human *neuroD2* proteins. Similar analyses indicated that mouse *neuroD3* contains an HLH domain between amino acid residues 109-148 of SEQ ID NO:22 (corresponding to nucleotides 425-544 of SEQ ID NO:21)

15 Brief Description of the Drawings

FIGURE 1 schematically depicts the domain structure of the murine and *Xenopus* *neuroD* bHLH proteins.

Detailed Description of the Preferred Embodiment

20 Tissue-specific bHLH proteins that regulate early neuroectodermal differentiation were discovered using expression cloning and screening assays designed to identify possible bHLH proteins capable of interacting with the protein product of the *Drosophila daughterless* gene. These proteins belong to a family of proteins that share conserved residues in the HLH region. The subject invention provides *neuroD2* and *neuroD3*, which are two novel genes related to *neuroD1*, and which have been isolated and whose nucleotide sequences have been determined. The term "neuroD," as used here, encompasses all members of the *neuroD* family, and includes *neuroD1*, *neuroD2* and *neuroD3* coding sequences and proteins.

30 The *neuroD* family of genes function during the development of the nervous system. Like *MATH1* (Lo et al., Genes & Dev. 5:1524-1537, 1991), the expression of *neuroD3* peaks during embryonic development and is not detected in the mature nervous system. *NeuroD2* shows a high degree of sequence similarity to both *neuroD1* and *NEX-1/MATH2*, and is similarly expressed both during embryogenesis and in the mature nervous system, demonstrating an expression pattern that partially overlaps with *neuroD1*. Like *neuroD1*, *neuroD2* when expressed by transfection in *Xenopus* embryos induces neurogenesis in ectodermal cells. Transfection of

expression vectors for *neuroD1* and *neuroD2* indicates that these highly similar transcription factors demonstrate some target specificity, with the *GAP-43* promoter being activated by *neuroD2* and not by *neuroD1*. The partially overlapping expression pattern and target specificity of *neuroD1* and *neuroD2* suggests that this group of neurogenic transcription factors may contribute to the establishment of neuronal identity in the nervous system by acting on an overlapping but non-congruent set of target genes.

NeuroD proteins are transiently expressed in differentiating neurons during embryogenesis. NeuroD proteins are also detected in adult brain, in the granule layer of the hippocampus and the cerebellum. In addition, murine *neuroD1* expression has been detected in the pancreas and gastrointestinal tissues of developing embryos and post-natal mice (see, e.g., Example 14).

NeuroD proteins contain the basic helix-loop-helix (bHLH) domain structure that has been implicated in the binding of bHLH proteins to upstream recognition sequences and activation of downstream target genes. The present invention provides representative neuroD proteins, which include the murine *neuroD1* protein of SEQ ID NO:2, the amphibian *neuroD1* protein of SEQ ID NO:4, murine *neuroD2* protein of SEQ ID NO:17, human *neuroD1* protein of SEQ ID NOS:9 and 15, human *neuroD2* protein of SEQ ID NO:11, human *neuroD3* protein of SEQ ID NO:13, and mouse *neuroD3* protein SEQ ID NO:22. Based on homology with other bHLH proteins, the bHLH domain for murine *neuroD1* is predicted to reside between amino acids 102 and 155 of SEQ ID NO:2, and between amino acids 101 and 157 of SEQ ID NO:4 for the amphibian *neuroD1*.

As detailed below, the present invention provides the identification of human *neuroD1* and, in addition, provides unexpected homologous genes of the same family based on highly conserved sequences across the HLH domain shared between the two human genes at the amino acid level (*neuroD2* and *neuroD3*; SEQ ID NOS:10 and 11, and 12 and 13, respectively).

NeuroD proteins are transcriptional activators that control transcription of downstream target genes including genes that among other activities cause neuronal progenitors to differentiate into mature neurons. In the neurula stage of the mouse embryo (e10), murine *neuroD1* is highly expressed in the neurogenic derivatives of neural crest cells, the cranial and dorsal root ganglia, and postmitotic cells in the central nervous system (CNS). During mouse development, *neuroD1* is expressed transiently and concomitant with neuronal differentiation in differentiating neurons in

sensory organs such as in nasal epithelium and retina. In *Xenopus* embryos, ectopic expression of *neuroD1* in non-neuronal cells induced formation of neurons. As discussed in more detail below, neuroD proteins are expressed in differentiating neurons and are capable of causing the conversion of non-neuronal cells into neurons.

- 5 The present invention encompasses variants of *neuroD* genes that, for example, are modified in a manner that results in a neuroD protein capable of binding to its recognition site, but unable to activate downstream genes. The present invention also encompasses fragments of neuroD proteins that, for example, are capable of binding the natural neuroD partner, but that are incapable of activating downstream genes.
- 10 NeuroD proteins encompass proteins retrieved from naturally occurring materials and closely related, functionally similar proteins retrieved by antisera specific to neuroD proteins, and recombinantly expressed proteins encoded by genetic materials (DNA, RNA, cDNA) retrieved on the basis of their similarity to the unique regions in the neuroD family of genes.

- 15 The present invention provides representative isolated and purified polynucleotide molecules encoding proteins of the neuroD family. Representative polynucleotide molecules encoding various neuroD proteins include the sequences presented in SEQ ID NOS:1, 3, 8, 10, 12, 14, and 16. Polynucleotide molecules encoding neuroD include those sequences resulting in minor genetic polymorphisms, differences between species, and those that contain amino acid substitutions,
- 20 additions, and/or deletions. According to the present invention, polynucleotide molecules encoding neuroD proteins encompass those molecules that encode neuroD proteins or peptides that share identity with the sequences shown in SEQ ID NOS:2, 4, 9, 11, 13, 15, and 17. Such molecules will generally share greater than 35% identity at the amino acid level with the disclosed sequences. The neuroD genes of
- 25 the present invention may share greater identity at the amino acid level across highly conserved regions such as the HLH domain. For example, the deduced amino acid sequences of murine and *Xenopus neuroD1* genes are 96% identical within this domain.

- 30 In some instances, one may employ such changes in the sequence of a recombinant *neuroD* polynucleotide molecule to substantially decrease or even increase the biological activity of neuroD protein relative to the wild-type neuroD activity, depending on the intended use of the preparation. Such changes may also be directed towards endogenous *neuroD* polynucleotide sequences using, for example,

gene therapy methods to alter the gene product. Such changes are envisioned with regard to *neuroD1*, *neuroD2*, *neuroD3*, or other members of the *neuroD* gene family.

The *neuroD1* proteins of the present invention are capable of inducing the expression in a frog embryo of neuron-specific genes, such as N-CAM, β -tubulin, and Xen-1, neurofilament M (NF-M), Xen-2, tanabin-1, shaker-1, and frog HSCL. As described below in Example 10, *neuroD1* activity may be detected when *neuroD* is ectopically expressed in frog oocytes following, for example, injection of *Xenopus neuroD1* RNA into one of the two cells in a two-cell stage *Xenopus* embryo, and monitoring expression of neuronal-specific genes in the injected as compared to uninjected side of the embryo by immunochemistry or *in situ* hybridization.

"Over-expression" means an increased level of a *neuroD* protein or of *neuroD* transcripts in a recombinant transformed host cell relative to the level of protein or transcripts in the parental cell from which the host cell is derived.

As noted above, the present invention provides isolated and purified polynucleotide molecules encoding various members of the *neuroD* family. The disclosed sequences may be used to identify and isolate additional *neuroD* polynucleotide molecules from suitable mammalian or non-mammalian host cells such as canine, ovine, bovine, caprine, lagomorph, or avian. In particular, the nucleotide sequences encoding the HLH region may be used to identify polynucleotide molecules encoding other proteins of the *neuroD* family. Complementary DNA molecules encoding *neuroD* family members may be obtained by constructing a cDNA library mRNA from, for example, fetal brain, newborn brain, and adult brain tissues. DNA molecules encoding *neuroD* family members may be isolated from such a library using the disclosed sequences to provide probes to be used in standard hybridization methods (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor, NY, 1989, which is incorporated herein by reference), and Bothwell, Yancopoulos and Alt, *ibid.*) or by amplification of sequences using polymerase chain reaction (PCR) amplification (e.g., Loh et al., *Science* **243**:217-222, 1989; Frohman et al., *Proc. Natl. Acad. Sci. USA* **85**:8998-9002, 1988; Erlich (ed.), *PCR Technology: Principles and Applications for DNA Amplification*, Stockton Press, 1989; and Mullis et al., *PCR: The Polymerase Chain Reaction*, 1994, which are incorporated by reference herein in their entirety). In a similar manner, genomic DNA encoding *neuroD* proteins may be obtained using probes designed from the sequences disclosed herein. Suitable probes for use in identifying *neuroD* genes or transcripts may be obtained from *neuroD*-specific sequences that are highly conserved

regions between mammalian and amphibian *neuroD* coding sequences. Nucleotide sequences, for example, from the region encoding the approximately 40 residues following the helix-2 domain are suitable for use in designing PCR primers. Alternatively, oligonucleotides containing specific DNA sequences from a human
5 *neuroD1*, *neuroD2*, or *neuroD3* coding region may be used within the described methods to identify related human *neuroD* genomic and cDNA clones. Upstream regulatory regions of *neuroD* may be obtained using the same methods. Suitable PCR primers are between 7-50 nucleotides in length, more preferably between 15 and 25 nucleotides in length. Alternatively, *neuroD* polynucleotide molecules may be
10 isolated using standard hybridization techniques with probes of at least about 15 nucleotides in length and up to and including the full coding sequence. Southern analysis of mouse genomic DNA probed with the murine *neuroD1* cDNA under stringent conditions showed the presence of only one gene, suggesting that under stringent conditions bHLH genes from other protein families will not be identified.
15 Other members of the *neuroD* family can be identified using degenerate oligonucleotides based on the sequences disclosed herein for PCR amplification or by hybridization at moderate stringency using probes based on the disclosed sequences.

The regulatory regions of *neuroD* may be useful as tissue-specific promoters. Such regulatory regions may find use in, for example, gene therapy to drive the tissue-specific expression of heterologous genes in pancreatic, gastrointestinal, or neural
20 cells, tissues or cell lines. As shown in Example 14, murine *neuroD1* promoter sequences reside within the 1.4 kb 5' untranslated region. Regulatory sequences within this region are identified by comparison to other promoter sequences and/or deletion analysis of the region itself.

25 In other aspects of the invention, a DNA molecule coding a *neuroD* protein is inserted into a suitable expression vector, which is in turn used to transfect or transform a suitable host cell. Suitable expression vectors for use in carrying out the present invention include a promoter capable of directing the transcription of a polynucleotide molecule of interest in a host cell and may also include a transcription
30 termination signal, these elements being operably linked in the vector. Representative expression vectors may include both plasmid and/or viral vector sequences. Suitable vectors include retroviral vectors, vaccinia viral vectors, CMV viral vectors, BLUESCRIPT® vectors, baculovirus vectors, and the like. Promoters capable of directing the transcription of a cloned gene or cDNA may be inducible or constitutive
35 promoters and include viral and cellular promoters. For expression in mammalian

host cells, suitable viral promoters include the immediate early cytomegalovirus promoter (Boshart et al., *Cell* 41:521-530, 1985) and the SV40 promoter (Subramani et al., *Mol. Cell. Biol.* 1:854-864, 1981). Suitable cellular promoters for expression of proteins in mammalian host cells include the mouse metallothionein-1 promoter (Palmiter et al., U.S. Patent No. 4,579,821), a mouse Vk promoter (Bergman et al., *Proc. Natl. Acad. Sci. USA* 81:7041-7045, 1983; Grant et al. *Nucleic Acid. Res.* 15:5496, 1987), and tetracycline-responsive promoter (Gossen and Bujard, *Proc. Natl. Acad. Sci. USA* 89:5547-5551, 1992, and Pescini et al., *Biochem. Biophys. Res. Comm.* 202:1664-1667, 1994). Also contained in the expression vectors, typically, is a transcription termination signal located downstream of the coding sequence of interest. Suitable transcription termination signals include the early or late polyadenylation signals from SV40 (Kaufman and Sharp, *Mol. Cell. Biol.* 2:1304-1319, 1982), the polyadenylation signal from the Adenovirus 5 e1B region, and the human growth hormone gene terminator (DeNoto et al., *Nucleic Acid. Res.* 9:3719-3730, 1981). Mammalian cells, for example, may be transfected by a number of methods including calcium phosphate precipitation (Wigler et al., *Cell* 14:725, 1978; Corsaro and Pearson, *Somatic Cell Genetics* 7:603, 1981; Graham and Van der Eb, *Virology* 52:456, 1973), lipofection, microinjection, and electroporation (Neumann et al., *EMBO J.* 1:8410845, 1982). Mammalian cells can be transduced with viruses such as SV40, CMV, and the like. In the case of viral vectors, cloned DNA molecules may be introduced by infection of susceptible cells with viral particles. Retroviral vectors may be preferred for use in expressing neuroD proteins in mammalian cells particularly if the *neuroD* genes used for gene therapy (for review, see, Miller et al. *Methods in Enzymology* 217:581-599, 1994; which is incorporated herein by reference in its entirety). It may be preferable to use a selectable marker to identify cells that contain the cloned DNA. Selectable markers are generally introduced into the cells along with the cloned DNA molecules and include genes that confer resistance to drugs, such as neomycin, hygromycin, and methotrexate. Selectable markers may also complement auxotrophs in the host cell. Yet other selectable markers provide detectable signals, such as β -galactosidase to identify cells containing the cloned DNA molecules. Selectable markers may be amplifiable. Such amplifiable selectable markers may be used to amplify the number of sequences integrated into the host genome.

As would be evident to one of ordinary skill in the art, the polynucleotide molecules of the present invention may be expressed in *Saccharomyces cerevisiae*,

filamentous fungi, and *E. coli*. Methods for expressing cloned genes in *Saccharomyces cerevisiae* are generally known in the art (see, "Gene Expression Technology," *Methods in Enzymology*, Vol. 185, Goeddel (ed.), Academic Press, San Diego, CA, 1990; and "Guide to Yeast Genetics and Molecular Biology," *Methods in Enzymology*, Guthrie and Fink (eds.), Academic Press, San Diego, CA, 1991, which are incorporated herein by reference). Filamentous fungi may also be used to express the proteins of the present invention; for example, strains of the fungi *Aspergillus* (McKnight et al., U.S. Patent No. 4,935,349, which is incorporated herein by reference). Methods for expressing genes and cDNAs in cultured mammalian cells and in *E. coli* are discussed in detail in Sambrook et al., 1989. As will be evident to one skilled in the art, one can express the protein of the instant invention in other host cells such as avian, insect, and plant cells using regulatory sequences, vectors and methods well established in the literature.

NeuroD proteins produced according to the present invention may be purified using a number of established methods such as affinity chromatography using anti-neuroD antibodies coupled to a solid support. Fusion proteins of antigenic tag and neuroD can be purified using antibodies to the tag. Additional purification may be achieved using conventional purification means such as liquid chromatography, gradient centrifugation, and gel electrophoresis, among others. Methods of protein purification are known in the art (see generally, Scopes, R., *Protein Purification*, Springer-Verlag, NY, 1982, which is incorporated herein by reference) and may be applied to the purification of recombinant neuroD described herein.

The term "capable of hybridizing under stringent conditions" as used herein means that the subject nucleic acid molecules (whether DNA or RNA) anneal under stringent hybridization conditions to an oligonucleotide of 15 or more contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14 or SEQ ID NO:16. It is generally known that oligonucleotides 15 nucleotides or more in length are extremely unlikely to be represented more than once in a mammalian genome, hence such oligonucleotides can form specific hybrids (see, for example, Sambrook et al., *Molecular Cloning*, [2d ed.], Cold Spring Harbor Laboratory Press, 1989, at Section 11.7).

"Stringent hybridization" is generally understood in the art to mean that the nucleic acid duplexes that form during the hybridization reaction are perfectly matched or nearly perfectly matched. Several rules governing nucleic acid hybridization have been well established. For example, it is standard practice to

achieve stringent hybridization for polynucleotide molecules >200 nucleotides in length by hybridizing at a temperature 15°-25°C below the melting temperature (T_m) of the expected duplex, and 5°-10°C below the T_m for oligonucleotide probes (e.g., Sambrook et al., at Section 11.45).

5 The T_m of a nucleic acid duplex be calculated using a formula based on the % G+C contained in the nucleic acids, and that takes chain length into account, such as the formula $T_m = 81.5 - 16.6 (\log [Na^+]) + 0.41 (\% G+C) - (600/N)$, where N = chain length (Sambrook et al., 1989, at Section 11.46). It is apparent from this formula that the effects of chain length on T_m is significant only when rather short
10 nucleic acids are hybridized, and also that the length effect is negligible for nucleic acids longer than a few hundred bases.

 The choice of hybridization conditions will be evident to one skilled in the art and will generally be guided by the purpose of the hybridization, the type of hybridization (DNA-DNA or DNA-RNA), and the level of desired relatedness
15 between the sequences. As discussed above, methods for hybridization are well established in the literature. See also, for example: Sambrook et al., *ibid.*; Hames and Higgins, eds., *Nucleic Acid Hybridization, A Practical Approach*, IRL Press, Washington DC, 1985; Berger and Kimmel, eds., *Methods in Enzymology, Vol. 52, Guide to Molecular Cloning Techniques*, Academic Press Inc., New York, NY, 1987;
20 and Bothwell, Yancopoulos and Alt, eds., *Methods for Cloning and Analysis of Eukaryotic Genes*, Jones and Bartlett Publishers, Boston, MA 1990; which are incorporated by reference herein in their entirety. One of ordinary skill in the art realizes that the stability of nucleic acid duplexes will decrease with an increased number and location of mismatched bases; thus, the stringency of hybridization may
25 be used to maximize or minimize the stability of such duplexes. Hybridization stringency can be altered by: adjusting the temperature of hybridization; adjusting the percentage of helix-destabilizing agents, such as formamide, in the hybridization mix; and adjusting the temperature and/or salt concentration of the wash solutions. In general, the stringency of hybridization is adjusted during the post-hybridization
30 washes by varying the salt concentration and/or the temperature. Stringency of hybridization may be reduced by reducing the percentage of formamide in the hybridization solution or by decreasing the temperature of the wash solution. High stringency conditions may involve high temperature hybridization (e.g., 65-68°C in aqueous solution containing 4-6 X SSC (1 X SSC = 0.15 M NaCl, 0.015 M sodium citrate), or 42°C in 50% formamide) combined washes at high temperature (e.g., 5-
35

25°C below the T_m), in a solution having a low salt concentration (e.g., 0.1 X SSC). Low stringency conditions may involve lower hybridization temperatures (e.g., 35-42°C in 20-50% formamide) with washes conducted at an intermediate temperature (e.g., 40-60°C) and in a wash solution having a higher salt concentration (e.g., 2-6 X SSC). Moderate stringency conditions, which may involve hybridization in 0.2-0.3M NaCl at a temperature between 50°C and 65°C and washes in 0.1 X SSC, 0.1% SDS at between 50°C and 55°C, may be used in conjunction with the disclosed polynucleotide molecules as probes to identify genomic or cDNA clones encoding members of the *neuroD* family.

The invention provides isolated and purified polynucleotide molecules encoding neuroD proteins that are capable of hybridizing under stringent conditions to an oligonucleotide of 15 or more contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, and/or SEQ ID NO:16, and also including the polynucleotide molecules complementary to the coding strands. The subject isolated *neuroD* polynucleotide molecules preferably encode neuroD proteins that trigger differentiation in ectodermal cells, particularly neuroectodermal stem cells, and in more committed cells of that lineage, for example, epidermal precursor cells, pancreatic and gastrointestinal cells. Such neuroD expression products typically form heterodimeric bHLH protein complexes that bind in the 5'-regulatory regions of target genes and enhance or suppress transcription of the target gene.

In some instances, cancer cells may contain a non-functional neuroD protein or may contain no neuroD protein due to genetic mutation or somatic mutations such that these cells fail to differentiate. For cancers of this type, the cancer cells may be treated in a manner to cause the over-expression of wild-type neuroD protein to force differentiation of the cancer cells.

Antisense *neuroD* nucleotide sequences, that is, nucleotide sequences complementary to the non-transcribed strand of a *neuroD* gene, may be used to block expression of mutant *neuroD* expression in neuronal precursor cells to generate and harvest neuronal stem cells. The use of antisense oligonucleotides and their applications have been reviewed in the literature (see, for example, Mol and Van der Krul, eds., *Antisense Nucleic Acids and Proteins Fundamentals and Applications*, New York, NY, 1992; which is incorporated by reference herein in its entirety). Suitable antisense oligonucleotides are at least 11 nucleotide in length and may include untranslated (upstream or intron) and associated coding sequences. As will be

evident to one skilled in the art, the optimal length of an antisense oligonucleotide depends on the strength of the interaction between the antisense oligonucleotide and the complementary mRNA, the temperature and ionic environment in which translation takes place, the base sequence of the antisense oligonucleotide, and the presence of secondary and tertiary structure in the target mRNA and/or in the antisense oligonucleotide. Suitable target sequences for antisense oligonucleotides include intron-exon junctions (to prevent proper splicing), regions in which DNA/RNA hybrids will prevent transport of mRNA from the nucleus to the cytoplasm, initiation factor binding sites, ribosome binding sites, and sites that interfere with ribosome progression. A particularly preferred target region for antisense oligonucleotide is the 5' untranslated (promoter/enhancer) region of the gene of interest. Antisense oligonucleotides may be prepared by the insertion of a DNA molecule containing the target DNA sequence into a suitable expression vector such that the DNA molecule is inserted downstream of a promoter in a reverse orientation as compared to the gene itself. The expression vector may then be transduced, transformed or transfected into a suitable cell resulting in the expression of antisense oligonucleotides. Alternatively, antisense oligonucleotides may be synthesized using standard manual or automated synthesis techniques. Synthesized oligonucleotides may be introduced into suitable cells by a variety of means including electroporation, calcium phosphate precipitation, liposomes, or microinjection. The selection of a suitable antisense oligonucleotide administration method will be evident to one skilled in the art. With respect to synthesized oligonucleotides, the stability of antisense oligonucleotide-mRNA hybrids may be increased by the addition of stabilizing agents to the oligonucleotide. Stabilizing agents include intercalating agents that are covalently attached to either or both ends of the oligonucleotide. Oligonucleotides may be made resistant to nucleases by, for example, modifications to the phosphodiester backbone by the introduction of phosphotriesters, phosphonates, phosphorothioates, phosphoroselenoates, phosphoramidates, or phosphorodithioates. Oligonucleotides may also be made nuclease resistant by synthesis of the oligonucleotides with alpha-anomers of the deoxyribonucleotides.

NeuroD proteins bind to 5' regulatory regions of neurogenic genes that are involved in neuroectodermal differentiation, including development of neural and endocrine tissues. As described in more detail herein, murine neuroD1 has been detected in neuronal, pancreatic and gastrointestinal tissues in embryonic and adult mice suggesting that neuroD1 functions in the transcription regulation in these tissues.

NeuroD proteins alter the expression of subject genes by, for example, down-regulating or up-regulating transcription, or by inducing a change in transcription to an alternative open reading frame. The subject polynucleotide molecules find a variety of uses, e.g., in preparing oligonucleotide probes, expression vectors, and transformed host cells, as disclosed below in the following Examples.

DNA sequences recognized by the various neuroD proteins may be determined using a number of methods known in the literature including immunoprecipitation (Biedenkapp et al, *Nature* 335:835-837, 1988; Kinzler and Vogelstein, *Nuc. Acids Res.* 17:3645-3653, 1989; and Sompayrac and Danna, *Proc. Natl. Acad. Sci. USA* 87:3274-3278, 1990; which are incorporated by reference herein), protein affinity columns (Oliphant et al., *Mol. Cell. Biol.* 9:2944-2949, 1989; which is incorporated by reference herein), gel mobility shifts (Blackwell and Weintraub, *Science* 250:1104-1110, 1990; which is incorporated by reference herein), and Southwestern blots (Keller and Maniatis, *Nuc. Acids Res.* 17:4675-4680, 1991; which is incorporated by reference herein).

One embodiment of the present invention involves the construction of inter-species hybrid neuroD proteins and hybrid neuroD proteins containing at least one domain from two or more neuroD family members to facilitate structure-function analyses or to alter neuroD activity by increasing or decreasing the neuroD-mediated transcriptional activation of neurogenic genes relative to the wild-type neuroD(s). Hybrid proteins of the present invention may contain the replacement of one or more contiguous amino acids of the native neuroD protein with the analogous amino acid(s) of neuroD from another species or other protein of the neuroD family. Such interspecies or interfamily hybrid proteins include hybrids having whole or partial domain replacements. Such hybrid proteins are obtained using recombinant DNA techniques. Briefly, DNA molecules encoding the hybrid neuroD proteins of interest are prepared using generally available methods such as PCR mutagenesis, site-directed mutagenesis, and/or restriction digestion and ligation. The hybrid DNA is then inserted into expression vectors and introduced into suitable host cells. The biological activity may be assessed essentially as described in the assays set forth in more detail in the Examples that follow.

The invention also provides synthetic peptides, recombinantly derived peptides, fusion proteins, and the like that include a portion of neuroD or the entire protein. The subject peptides have an amino acid sequence encoded by a nucleic acid which hybridizes under stringent conditions with an oligonucleotide of 15 or more

contiguous nucleotides of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, or SEQ ID NO:16. Representative amino acid sequences of the subject peptides are disclosed in SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, and SEQ ID NO:17. The subject peptides find a variety of uses, including preparation of specific antibodies and preparation of agonists and antagonists of neuroD activity.

As noted above, the invention provides antibodies that bind to neuroD proteins. The production of non-human antisera or monoclonal antibodies (e.g., murine, lagomorph, porcine, equine) is well known and may be accomplished by, for example, immunizing an animal with neuroD protein or peptides. For the production of monoclonal antibodies, antibody producing cells are obtained from immunized animals, immortalized and screened, or screened first for the production of the antibody that binds to the neuroD protein or peptides and then immortalized. It may be desirable to transfer the antigen binding regions (e.g., F(ab')₂ or hypervariable regions) of non-human antibodies into the framework of a human antibody by recombinant DNA techniques to produce a substantially human molecule. Methods for producing such "humanized" molecules are generally well known and described in, for example, U.S. Patent No. 4,816,397; which is incorporated by reference herein in its entirety. Alternatively, a human monoclonal antibody or portions thereof may be identified by first screening a human B-cell cDNA library for DNA molecules that encode antibodies that specifically bind to the neuroD family member, e.g., according to the method generally set forth by Huse et al. (*Science* 246:1275-1281, 1989, which is incorporated by reference herein in its entirety). The DNA molecule may then be cloned and amplified to obtain sequences that encode the antibody (or binding domain) of the desired specificity.

The invention also provides methods for inducing the expression of genes associated with neuronal phenotype in a cell that does not normally express those genes. Examples of neuronal phenotypes that may be modulated by neuroD expression include expression of neurotransmitters or neuromodulatory factors. Cells that can be used for the purpose of modulation of gene expression by neuroD include cells of the neuroectodermal lineage, glial cells, neural crest cells, and epidermal epithelial basal stem cells, and all types of both mesodermal and endodermal lineage cells. NeuroD expression may also be used within methods that induce expression of genes associated with pancreatic and gastrointestinal phenotype. Examples of such

gene expression include insulin expression, and gastrointestinal-specific enzyme expression.

As illustrated in Example 10, the expression of *Xenopus* neuroD1 protein in stem cells causes redirection of epidermal cell differentiation and induces terminal differentiation into neurons, i.e., instead of epidermal cells. Epithelial basal stem cells (i.e., in skin and mucosal tissues) are one of the few continuously regenerating cell types in an adult mammal. Introduction of the subject nucleotide sequences into an epithelial basal stem cell may be accomplished *in vitro* or *in vivo* using a suitable gene therapy vector delivery system (e.g., a retroviral vector), a microinjection technique (see, for example, Tam, *Basic Life Sciences* 37:187-194, 1986, which is incorporated by reference herein in its entirety), or a transfection method (e.g., naked or liposome encapsulated DNA or RNA; see, for example, *Trends in Genetics* 5:138, 1989; Chen and Okayama, *Biotechniques* 6:632-638, 1988; Mannino and Gould-Fogerite, *Biotechniques* 6:682-690, 1988; Kojima et al., *Biochem. Biophys. Res. Comm.* 207:8-12, 1995; which are incorporated by reference herein in their entirety). The introduction method may be chosen to achieve a transient expression of neuroD in the host cell, or it may be preferable to achieve constitutive or regulated expression in a tissue specific manner.

Transformed host cells of the present invention find a variety of *in vitro* uses, for example: i) as convenient sources of neuronal and other growth factors, ii) in transient and continuous cultures for screening anti-cancer drugs capable of driving terminal differentiation in neural tumors, iii) as sources of recombinantly expressed neuroD protein for use as an antigen in preparing monoclonal and polyclonal antibodies useful in diagnostic assays, and iv) in transient and continuous cultures for screening for compounds capable of increasing or decreasing the activity of neuroD.

Transformed host cells of the present invention also find a variety of *in vivo* uses, for example, for transplantation at sites of traumatic neural injury where motor or sensory neural activity has been lost. Representative patient populations that may benefit from transplantation include: patients with hearing or vision loss due to optical or auditory nerve damage, patients with peripheral nerve damage and loss of motor or sensory neural activity, and patients with brain or spinal cord damage from traumatic injury. For example, donor cells from a patient such as epithelial basal stem cells are cultured *in vitro* and then transformed or transduced with a *neuroD* nucleotide sequence. The transformed cells are then returned to the patient by microinjection at the site of neural dysfunction. In addition, as neuroD appears

capable of regulating expression of insulin, transformed host cells of the present invention may be useful for transplantation into patients with diabetes. For example, donor cells from a patient such as fibroblasts, pancreatic islet cells, or other pancreatic cells are harvested and transformed or transfected with a *neuroD* nucleotide sequence.

- 5 The genetically engineered cells are then returned to the patient. In another embodiment, such engineered host cells may find use in the treatment of malabsorption syndromes.

Representative uses of the nucleotide sequences of the invention include the following:

- 10 1. Construction of cDNA and oligonucleotide probes useful in Northern or Southern blots, dot-blots, or PCR assays for identifying and quantifying the level of expression of *neuroD* in a cell. High level expression of *neuroD* in neuroendocrine tumors and in rapidly proliferating regions of embryonic neural development (see below) indicates that measuring the level of *neuroD* expression may provide
15 prognostic markers for assessing the growth rate and invasiveness of a neural tumor. In addition, considering the important role of *neuroD* in embryonic development it is thought highly likely that birth defects and spontaneous abortions may result from expression of an abnormal *neuroD* protein. In this case, *neuroD* may prove highly useful in prenatal screening of mothers and/or for *in utero* testing of fetuses.
- 20 2. Construction of recombinant cell lines, ova, and transgenic embryos and animals including dominant-negative and "knock-out" recombinant cell lines in which the transcription regulatory activity of *neuroD* protein is down-regulated or eliminated. Such cells may contain altered *neuroD* coding sequences that result in the expression of a *neuroD* protein that is not capable of enhancing, suppressing or
25 activating transcription of the target gene. The subject cell lines and animals find uses in screening for candidate therapeutic agents capable of either substituting for a function performed by *neuroD* or correcting the cellular defect caused by a defective *neuroD*. Considering the important regulatory role of *neuroD* in embryonic development, birth defects may occur from expression of mutant *neuroD* proteins,
30 and these defects may be correctable *in utero* or in early post-natal life through the use of compounds identified in screening assays using *neuroD*. In addition, *neuroD* polynucleotide molecules may be joined to reporter genes, such as β -galactosidase or luciferase, and inserted into the genome of a suitable embryonic host cell such as a mouse embryonic stem cell by, for example, homologous recombination (for review,
35 see Capecchi, *Trends in Genetics* 5:70-76, 1989; which is incorporated by reference).

Cells expressing neuroD may then be obtained by subjecting the differentiating embryonic cells to cell sorting, leading to the purification of a population of neuroblasts. Neuroblasts may be useful for studying neuroblast sensitivity to growth factors or chemotherapeutic agents. The neuroblasts may also be used as a source from which to purify specific protein products or gene transcripts. These products may be used for the isolation of growth factors, or for the identification of cell surface markers that can be used to purify stem cell population from a donor for transplantation.

As illustrated in Example 14, "knock-out" mice were generated by replacing the murine *neuroD1* coding region with the β -galactosidase reporter gene and the neomycin resistance gene to assess the consequences of eliminating the murine neuroD1 protein and to examine the tissue distribution of neuroD1 in fetal and postnatal mice. Mice that were homozygous for the mutation (lacking neuroD1) had diabetes, as demonstrated by high blood glucose levels, and died by day four. Homozygous mutants had blood glucose levels between 2 and 3 times the blood glucose level of wild-type mice. Heterozygous mutants exhibited similar blood glucose levels as wild-type mice. Examination of stained tissue from fetal and postnatal mice heterozygous for the mutation confirmed the neuroD1 expression pattern in neuronal cells demonstrated by *in situ* hybridization (Example 4) and also demonstrated neuroD expression in the pancreas and gastrointestinal tract.

"Knock-out" mice may be useful as a model system for diabetes. Such mice may be used to study methods to rescue homozygous mutants and as hosts to test transplant tissue for treating diabetes.

3. Construction of gene transfer vectors (e.g., retroviral vectors, and the like) wherein *neuroD* is inserted into the coding region of the vector under the control of a promoter. *NeuroD* gene therapy may be used to correct traumatic neural injury that has resulted in loss of motor or sensory neural function, and also for the treatment of diabetes. For these therapies, gene transfer vectors may either be injected directly at the site of the traumatic injury, or the vectors may be used to construct transformed host cells that are then injected at the site of the traumatic injury. The results disclosed in Example 10 indicate that introduction of *neuroD1* induces a non-neuronal cell to become a neuron. This discovery raises for the first time the possibility of using transplantation and/or gene therapy to repair neural defects resulting from traumatic injury. In addition, the discovery of *neuroD1* provides the possibility of providing specific gene therapy for the treatment of certain

neurological disorders such as Alzheimer's disease, Huntington's disease, and Parkinson's disease, in which a population of neurons have been damaged. Two basic methods of *neuroD1* utilization are envisioned in this regard. In one method, *neuroD1* is expressed in existing populations of neurons to modulate aspects of their neuronal phenotype (e.g., neurotransmitter expression or synapse targeting) to make the neurons express a factor or phenotype to overcome the deficiency that contributes to the disease. In this method, recombinant *neuroD1* sequences are introduced into existing neurons or endogenous *neuroD1* expression is induced. In another method, *neuroD1* is expressed in non-neuronal cells (e.g., glial cells in the brain or another non-neuronal cell type such as basal epithelial cells) to induce expression of genes that confer a complete or partial neuronal phenotype that ameliorates aspects of the disease. As an example, Parkinson's disease is caused, at least in part, by the death of neurons that supply the neurotransmitter dopamine to the basal ganglia. Increasing the levels of neurotransmitter ameliorates the symptoms of Parkinson's disease. Expression of *neuroD1* in basal ganglia neurons or glial cells may induce aspects of a neuronal phenotype such that the neurotransmitter dopamine is produced directly in these cells. It may also be possible to express *neuroD1* in donor cells for transplantation into the affected region, either as syngeneic or allogeneic transplantations. Within yet another embodiment, *neuroD1* is expressed in non-pancreatic cells to induce expression of genes that confer a complete or partial pancreatic phenotype that ameliorates aspects of diabetes. Within yet another embodiment, *neuroD1* is expressed in pancreatic islet cells to induce expression of genes that induce the expression of insulin.

4. Preparation of transplantable recombinant neuronal precursor cell populations from embryonic ectodermal cells, non-neural basal stem cells, and the like. Establishing cultures of non-malignant neuronal cells for use in therapeutic screening assays has proven to be a difficult task. The isolated polynucleotide molecules encoding *neuroD* proteins of the present invention permit the establishment of primary (or continuous) cultures of proliferating embryonic neuronal stem cells under conditions mimicking those that are active in development and cancer. The resultant cell lines find uses: i) as sources of novel neural growth factors, ii) in screening assays for anti-cancer compounds, and iii) in assays for identifying novel neuronal growth factors. For example, a high level of expression of *neuroD* was observed in the embryonic optic tectum, indicating that *neuroD1* protein may regulate expression of factors trophic for growing retinal cells. Such cells may be useful

sources of growth factors, and may be useful in screening assays for candidate therapeutic compounds.

The cell lines and transcription regulatory factors disclosed herein offer the unique advantage that since they are active very early in embryonic differentiation they represent potential switches, e.g., ON→OFF or OFF→ON, controlling subsequent cell fate. If the switch can be shown to be reversible (i.e., ON↔OFF), the *neuroD* transcription regulatory factor and *neuroD* nucleic acids disclosed herein provide exciting opportunities for restoring lost neural and/or endocrine functions in a subject.

The following examples are offered by way of illustration and not by way of limitation.

EXAMPLE 1

Construction of the embryonic stem cell "179" cDNA library.

A continuous murine embryonic stem cell line (i.e., the ES cell line) having mutant E2A (the putative binding partner of *myoD*) was used as a cell source to develop a panel of embryonic stem cell tumors. Recombinant ES stem cells were constructed (i.e., using homologous recombination) wherein both alleles of the putative *myoD* binding partner E2A were replaced with drug-selectable marker genes. ES cells do not make functional E12 or E47 proteins, both of which are E2A gene products. ES cells form subcutaneous tumors in congenic mice (i.e., strain 129J) that appear to contain representatives of many different embryonal cell types as judged histologically and through the use of RT-PCR gene expression assays. Individual embryonic stem cell tumors were induced in male 129J strain mice by subcutaneous injection of 1×10^7 cells/site. Three weeks later each tumor was harvested and used to prepare an individual sample of RNAs. Following random priming and second strand synthesis the ds-cDNAs were selected based on their size on 0.7% agarose gels and those cDNAs in the range of 400-800 bp were ligated to either Bam HI or Bgl II linkers. (Linkers were used to minimize the possibility that an internal Bam HI site in a cDNA might inadvertently be cut during cloning, leading to an abnormally sized or out-of-frame expression product.) The resultant individual stem cell tumor DNAs were individually ligated into the Bam HI cloning site in the "f1-VP16" 2 μ yeast expression vector. This expression vector, f1-VP16, contains the VP16 activation domain of Herpes simplex virus (HSV) located between Hind III (HIII) and Eco RI (RI) sites and under the control of the *Saccharomyces cerevisiae* alcohol dehydrogenase promoter; with *LEU2* and Ampicillin-resistance selectable markers.

Insertion of a DNA molecule of interest into the Hind III site of the fl-VP16 vector (i.e., 5' to the VP16 nucleotide sequence), or into a Bam HI site (i.e., 3' to the VP16 sequence but 5' to the Eco RI site), results in expression of a VP16 fusion protein having the protein of interest joined in-frame with VP16. The resultant cDNA library was termed the "179-library".

EXAMPLE 2

Identification and cDNA cloning of mouse *neuroD1*.

A two-hybrid yeast screening assay was used essentially as described by Fields and Song (*Nature* 340:245, 1989) and modified as described herein was used to screen the 179-library described in Example 1. Yeast two-hybrid screens are reviewed as disclosed in Fields and Sternglanz (*Trends in Genetics* 10:286-292, 1994). The library was screened for cDNAs that interacted with LexA-Da, a fusion protein between the *Drosophila* Da (Daughterless) bHLH domain and the prokaryotic LexA-DNA binding domain. The *S. cerevisiae* strain L40 contained multimerized LexA binding sites cloned upstream of two reporter genes, namely, the *HIS3* gene, and the β -galactosidase gene, each of which was integrated into the L40 genome. The *S. cerevisiae* strain L40 containing a plasmid encoding the LexA-Da fusion protein was transformed with CsCl gradient-purified fl-VP16-179-cDNA library. Transformants were maintained on medium selecting both plasmids (the LexA-Da plasmid and the cDNA library plasmid) for 16 hours before being subjected to histidine selection on plates lacking histidine, leucine, tryptophan, uracil, and lysine. Clones that were HIS^+ were subsequently assayed for the expression of *LacZ*. To eliminate possible non-specific cloning artifacts, plasmids from $HIS^+/LacZ^+$ were isolated and transformed into *S. cerevisiae* strain L40 containing a plasmid encoding a LexA-Lamin fusion. Clones that scored positive in the interaction with lamin were discarded. Approximately 400 cDNA clones, which represented 60 different transcripts, were identified as positive in these assays. Twenty-five percent of the original clones were subsequently shown to be known bHLH genes on the basis of their reactivity with specific cDNA probes. One cDNA clone encoding a VP16-fusion protein that interacted with Da but not lamin was identified as unique by sequence analysis. This clone, initially termed *tango*, is now referred to as *neuroD1*.

The unique cDNA identified above, VP16-*neuroD*, contained an approximately 450 bp insert that spanned the bHLH region. Sequence analysis showed that the clone contained an insert encoding a complete bHLH amino acid sequence motif that was unique and previously unreported. Further analysis

suggested that while the cDNA contained conserved residues common to all members of the bHLH protein family, several residues were unique and made it distinct from previously identified bHLH proteins. The DNA cloned in VP16-*neuroD* is referred to as "neuroD1." The *neuroD1* cDNA insert was subcloned as a Bam HI-Not I insert into Bam HI-Not I linearized pBluescript SK⁺. The resulting plasmid was designated pSK+1-83.

The *neuroD1* insert contained in the VP16-*neuroD* plasmid was used to re-probe a mouse cDNA library prepared from mouse embryos at developmental stage e10.5. Candidate clones were isolated and sequenced essentially as described above. Several clones were isolated. One clone, designated pKS⁺ m7a RX, was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 USA, on May 6, 1994, under accession number 75768. Plasmid pKS⁺ m7a RX contains 1646 bp of murine *neuroD1* cDNA as an EcoRI-XhoI insert. The amino acid sequence encoded by the insert begins at amino acid residue +73 and extends to the carboxy-terminus of the neuroD1 protein. The plasmid contains about 855 bp of *neuroD1* coding sequence (encoding amino acids 73-536).

None of the mouse cDNAs contained the complete 5' coding sequence. To obtain the 5' *neuroD1* coding sequence, a mouse strain 129/Sv genomic DNA library was screened with the VP16-*neuroD* plasmid insert (450 bp). Genomic clones were isolated and sequenced and the sequences were aligned with the cDNA sequences. Alignment of the sequence and comparison of the genomic 5' coding sequences with the *Xenopus neuroD1* clone (Example 8) confirmed the 5' *neuroD1* coding sequence. The complete *neuroD1* coding sequence and deduced amino acid sequence are shown in SEQ ID NOS:1 and 2.

EXAMPLE 3

NeuroD/neuroD

bHLH proteins share common structural similarities that include a basic region that binds DNA and an HLH region involved in protein-protein interactions required for the formation of homodimers and heterodimeric complexes. A comparison of the amino acid sequence of the basic region of murine neuroD1 (amino acids 102 to 113 of SEQ ID NO:2) with basic regions of other bHLH proteins revealed that murine neuroD contained all of the conserved residues characteristic among this family of proteins. However, in addition, neuroD1 contained several unique residues. These unique amino acid residues were not found in any other known HLH, making neuroD1 a distinctive new member of the bHLH family. The NARERNR basic region

motif in *neuroD* (amino acids 107-113 of SEQ ID NO:2) is also found in the *Drosophila* AS-C protein, a protein thought to be involved in neurogenesis. Similar, but not identical, NARERRR and NERERNR motifs (SEQ ID NOS:5 and 6, respectively) have been found in the *Drosophila* Atonal and MASH (mammalian achaete-scute homolog) proteins, respectively, which are also thought to be involved in neurogenesis. The NARER motif (SEQ ID NO:7) of *neuroD1* is shared by other bHLH proteins, and the *Drosophila* Daughterless (Da) and Mammalian E proteins. The basic region of bHLH proteins is important for DNA binding site recognition, and there is homology between *neuroD1* and other neuro-proteins in this functional region. Within the important dimer-determining HLH region of *neuroD1*, a low level of homology was recorded with mouse twist protein (i.e., 51% homology) and with MASH (i.e., 46% homology). *NeuroD1* contains several regions of unique peptide sequence within the bHLH domain including the junction sequence (MHG).

EXAMPLE 4

Tissue expression patterns of *neuroD1*, *neuroD2*, and *neuroD3*

NeuroD1 expression was analyzed during embryonic development of mouse embryos using *in situ* hybridization. The probe used was an antisense *neuroD1* single-stranded riboprobe labeled with digoxigenin (Boehringer Mannheim). Briefly, a riboprobe was prepared from plasmid pSK+1-83 using T7 polymerase and digoxigenin-11-UTP for labeling. The hybridized probe was detected using anti-digoxigenin antibody conjugated with alkaline phosphatase. Color development was carried out according to the manufacturer's instructions. Stages of development are commonly expressed as days following copulation and where formation of the vaginal plug is e0.5. The results recorded in the *in situ* hybridization studies were as follows:

In the e9.5 mouse embryo, *neuroD1* expression was observed in the developing trigeminal ganglia.

In the e10.5 mouse embryo, a distinctive pattern of *neuroD1* expression was observed in all the cranial ganglia (i.e., V-XI) and in dorsal root ganglia (DRG) in the trunk region of the embryo. At this time, *neuroD1* expression was also observed in the central nervous system in post-mitotic cells in the brain and spinal cord that were undergoing neuronal differentiation. In the spinal cord, the ventral portion of the cord from which the motor neurons arise and differentiate was observed to express *neuroD1* at high levels; and expression in the posterior-ventral spinal cord was higher when compared to more mature anterior-ventral spinal cord.

In the e11.5 mouse embryo, the ganglionic expression pattern of *neuroD1* observed in e10.5 persisted. Expression in the spinal cord was increased over the level of expression observed in e10.5 embryos, which was consistent with the presence of more differentiating neurons at this stage. At this stage *neuroD1* expression was also observed in other sensory organs in which neuronal differentiation occurs, for example, in the nasal epithelium, otic vesicle, and retina of the eye. In both of these organs *neuroD1* expression was observed in the region containing differentiating neurons.

In the e14.5 mouse embryo, expression of *neuroD1* was observed in cranial ganglia and DRG, but expression of *neuroD1* persisted in the neuronal regions of developing sensory organs and the central nervous system (CNS). Thus, *neuroD1* expression was observed to be transient during neuronal development.

In summary, expression of *neuroD1* in the neurula stage of the embryo (e10), in the neurogenic derivatives of neural crest cells, the cranial and dorsal root ganglia, and post mitotic cells in the CNS suggests an important possible link between expression and generation of sensory and motor nerves. Expression occurring later in embryonic development in differentiating neurons in the CNS and in sensory organs (i.e., nasal epithelium and retina) also supports a role in development of the CNS and sensory nervous tissue. Since *neuroD1* expression was transient, the results suggest that *neuroD1* expression is operative as a switch controlling formation of sensory nervous tissue. It is noteworthy that in these studies *neuroD1* expression was not observed in embryonic sympathetic and enteric ganglia (also derived from migrating neural crest cells). Overall, the results indicate that *neuroD1* plays an important role in neuronal differentiation.

In addition to the *in situ* studies described above, Northern blot analysis was done to determine in what tissues of the mouse *neuroD1*, *neuroD2*, and *neuroD3* were expressed. Total RNA was isolated from whole mouse embryos and adult mouse tissues. RNA isolation was performed using RNazol B according to the protocol provided (Cinna/Biotex CS-105B). RNA was size fractionated on 1.5% agarose gels and transferred to Hybond-N membranes. Hybridization was carried out in 7% SDS, 0.25 M Na₂PO₄, 10mg/ml BSA, 1 mM EDTA at 65°C for at least 5 hours and then washed in 0.1X SSC and 0.1% SDS at 55°C-60°C. Probes for analyzing mouse mRNA were prepared from fragments representing the divergent carboxy-terminal regions 3-prime of the bHLH domain to avoid cross-hybridization between genes. Probe for *neuroD1* was made from a 350 base pair PstI fragment from the

mouse *neuroD1* cDNA (Lee et al., 1995) that encompasses the region coding for amino acids 187-304; probe for *neuroD2* was made from a 635 base pair PstI fragment from the mouse *neuroD2* cDNA that encompasses the region from amino acid 210 through to the 3-prime non-translated region; and probe for *neuroD3* was made from a 400 base pair ApaI-BamHI fragment from the *neuroD3* genomic region that is 3-prime to the region coding the bHLH domain.

After labeling with ^{32}P , the above-described fragments were used to probe Northern blots containing RNAs prepared from various tissues of newborn and adult mice. Both *neuroD1* and *neuroD2* were detected in the brain of both newborn and adult mice, whereas, *neuroD3* transcripts were not detected in any of the tissues tested. RNA extracted from dissected regions of the adult mouse nervous system demonstrated that *neuroD1* was more abundant in the cerebellum than the cortex, whereas *neuroD2* was expressed at relatively equivalent levels in both cerebellum and cortex.

To determine when during mouse embryonic development *neuroD2* and *neuroD3* were expressed in comparison to *neuroD1*, RNA was prepared from whole embryos at various developmental stages. In accord with previous reports (Lee et al., 1995), *neuroD1* mRNA was first detected at low levels at embryonic day 9.5 and at increasing levels through embryonic day 12.5, the latest embryonic stage tested. *NeuroD2* mRNA was first detected at embryonic day 11 and also increased in abundance through embryonic day 12.5. Although we did not detect *neuroD3* in the adult tissues, the embryonic expression pattern showed a transient expression between embryonic day 10 and 12 and then declined to undetectable levels by embryonic day 16. Collectively, these data demonstrate that *neuroD3* is expressed transiently during embryogenesis, similar to the expression pattern of *MATH1* (Akazawa et al., 1995), and that the temporal expression of *neuroD1* and *neuroD2* partly overlap with *neuroD3*, but that their expression persists in the adult nervous system.

EXAMPLE 5

NeuroD1 is expressed in neural and brain tumor cells: murine probes identify human *neuroD1*.

Given the expression pattern in mouse embryo (Example 4), Northern blots of tumor cell line mRNAs were examined using murine *neuroD1* cDNA (Example 2) as a molecular probe. As a first step, cell lines that have the potential for developing into neurons were screened. The D283 human medulloblastoma cell line, which expressed many neuronal markers, expressed high levels of *neuroD1* by Northern blot analysis.

NeuroD1 was also transcribed at various levels by different human neuroblastoma cell lines and in certain rhabdomyosarcoma lines that are capable of converting to neurons.

EXAMPLE 6

Recombinant cells expressing *NeuroD1*.

5 Recombinant murine 3T3 fibroblast cells expressing either a myc-tagged murine *neuroD1* protein or myc-tagged *Xenopus neuroD1* protein were made. The recombinant cells were used as a test system for identifying antibody to *neuroD* described below.

10 *Xenopus neuroD1* protein was tagged with the antigenic marker Myc to allow the determination of the specificity of anti-*neuroD1* antibodies to be determined. Plasmid CS2+MT was used to produce the Myc fusion protein. The CS2+MT vector (Turner and Weintraub, *ibid.*) contains the simian cytomegalovirus IE94 enhancer/promoter (and an SP6 promoter in the 5' untranslated region of the IE94-driven transcript to allow in vitro RNA synthesis) operatively linked to a DNA
15 sequence encoding six copies of the Myc epitope tag (Roth et al, *J. Cell Biol.* 115:587-596, 1991; which is incorporated herein in its entirety), a polylinker for insertion of coding sequences, and an SV40 late polyadenylation site. CS2-MT was digested with *Xho* I to linearize the plasmid at the polylinker site downstream of the DNA sequence encoding the Myc tag. The linearized plasmid was blunt-ended using
20 Klenow and dNTPs. A full length *Xenopus neuroD1* cDNA clone was digested with *Xho* I and *Eae* I and blunt-ended using Klenow and dNTPs, and the 1.245 kb fragment of the *Xenopus neuroD1* cDNA was isolated. The *neuroD1* fragment and the linearized vector were ligated to form plasmid CS2+MT x1-83.

25 CS2+MT was digested with *Eco* RI to linearize the plasmid at the polylinker site downstream of the DNA sequence encoding the Myc tag. The linearized plasmid was blunt-ended using Klenow and dNTPs and digested with *Xho* I to obtain a linearized plasmid having an *Xho* I adhesive end and a blunt end. Plasmid pKS+m7a containing a partial murine *neuroD1* cDNA was digested with *Xho* I, and the *neuroD1* containing fragment was blunt-ended and digested with *Xba* I to obtain the
30 approximately 1.6 kb fragment of the murine *neuroD1* cDNA. The *neuroD1* fragment and the linearized vector were ligated to form plasmid CS2+MT M1-83(m7a).

35 Plasmids CS2+MT x1-83 and CS2+MT M1-83(m7a) were each transformed into murine 3T3 fibroblast cells and used as a test system for identifying antibody against *neuroD1* (Example 7).

EXAMPLE 7

Antibodies to NeuroD1.

A recombinant fusion protein of maltose binding protein (MBP) and amino acid residues 70-355 of murine neuroD1 was used as an antigen to evoke antibodies in rabbits. Specificity of the resultant antisera was confirmed by immunostaining of the recombinant 3T3 cells described above. Double-immunostaining of the recombinant cells was observed with monoclonal antibodies to Myc (i.e., the control antigenic tag on the transfected DNA) and with rabbit anti-murine neuroD1 in combination with anti-rabbit IgG. The specificity of the resultant anti-murine neuroD1 sera was investigated further by preparing mouse 3T3 fibroblasts cells transfected with different portions of *neuroD1* DNA. Specificity seemed to map to the glutamic acid-rich domain (i.e., amino acids 66-73 of SEQ ID NO:2). The anti-murine antisera did not react with cells transfected with the myc-tagged *Xenopus* neuroD1. In a similar manner, *Xenopus* neuroD1 was used to generate rabbit anti-neuroD antisera. The antisera was *Xenopus*-specific and did not cross react with cells transfected with Myc-tagged murine *neuroD1*.

EXAMPLE 8

NeuroD1 is a highly evolutionarily conserved protein: sequence of *Xenopus* neuroD1.

Approximately one million clones from a stage 17 *Xenopus* head cDNA library made by Kintner and Melton (*Development* 99:311, 1987) were screened with the mouse cDNA insert as a probe at low stringency. The hybridization was performed with 50% formamide/4 X SSC at 33°C and washed with 2 X SSC/0.1% SDS at 40°C.

Positive clones were identified and sequenced. Analysis of the *Xenopus neuroD1* cDNA sequence (SEQ ID NO:3) revealed that neuroD1 is a highly conserved protein between frog and mouse. The deduced amino acid sequences of frog and mouse (SEQ ID NOS:2 and 4) show 96% identity in the bHLH domain (50 of 52 amino acids are identical) and 80% identity in the region that is carboxy-terminal to the bHLH domain (159 of 198 amino acids are identical). The domain structures of murine and *Xenopus* neuroD1 are highly homologous with an "acidic" N-terminal domain (i.e., glutamic or aspartic acid rich); a basic region; helix 1, loop, helix 2; and a proline rich C-terminal region. Although the amino terminal regions of murine and *Xenopus* neuroD1 differ in amino acid sequence, both retain a glutamic or aspartic acid rich "acidic domain" (amino acids 102 to 113 of SEQ ID NO:2 and amino acids 56 to 79 of SEQ ID NO:4). It is highly likely that the acidic domain constitutes an "activation" domain for the neuroD1 protein, in a manner analogous to

the activation mechanisms currently understood for other known transcription regulatory factors.

EXAMPLE 9

Neuronal expression of *Xenopus neuroD1*.

5 The expression pattern of *neuroD1* in whole mount *Xenopus* embryos was determined using *in situ* hybridization with a single stranded digoxigenin-labeled *Xenopus neuroD1* antisense cDNA riboprobe. Embryos were examined at several different stages.

10 Consistent with the mouse expression pattern, by late stage, all cranial ganglia showed very strong staining patterns. In *Xenopus*, as in other vertebrate organisms, neural crest cells give rise to skeletal components of the head, all ganglia of the peripheral nervous system, and pigment cells. Among these derivatives, the cranial sensory ganglia, which are of mixed crest and placode origin, represent the only group of cells that express *neuroD1*. High levels of *neuroD1* expression in the eye were also
15 observed, correlating with active neuronal differentiation in the retina at this stage. Expression is observed in the developing olfactory placodes and otic vesicles, as was seen in mice. The pineal gland also expressed *neuroD1*. All of this expression was transient, suggesting that *neuroD1* functions during the differentiation process but is not required for maintenance of these differentiated cell types.

20 As early as stage 14 (i.e., the mid-neurula stage) *neuroD1* expression was observed in the cranial neural crest region where trigeminal ganglia differentiate. Primary mechanosensory neurons in the spinal cord, also referred to as Rohon-Beard cells and primary motor neurons, showed *neuroD1* expression at this stage.

25 By stage 24, all of the developing cranial ganglia, trigeminal, facio-acoustic, glosso-pharyngeal, and vagal nervous tissues showed a high level of *neuroD1* expression. High levels of expression of *neuroD1* were also observed in the eye at this stage. (Note that in *Xenopus* neuronal differentiation in the retina occurs at a much earlier stage than in mice, and *neuroD1* expression was correspondingly earlier and stronger in this animal model.)

30 In summary, in *Xenopus* as in mouse, *neuroD1* expression was correlated with sites of neuronal differentiation. The remarkable evolutionary conservation of the pattern of *neuroD1* expression in differentiating neurons supports the notion that *neuroD1* has been evolutionarily conserved both structurally and functionally in these distant classes, which underscores the critical role performed by this protein in
35 embryonic development.

EXAMPLE 10

Expression of *neuroD1* and *neuroD2* converts non-neuronal cells into neurons.

To further analyze the biological functions of *neuroD1*, a gain-of-function assay was conducted. In this assay, RNA was microinjected into one of the two cells in a 2-cell stage *Xenopus* embryo, and the effects on later development of neuronal phenotype were evaluated. For these experiments *myc*-tagged *Xenopus neuroD1* transcripts were synthesized *in vitro* using SP6 RNA polymerase. The *myc*-tagged-*neuroD1* transcripts were microinjected into one of the two cells in a *Xenopus* 2-cell embryo, and the other cell of the embryo served as an internal control.

Synthesis of capped RNA for the *Xenopus laevis* injections was done essentially as described (Kreig, P. A. and D. A. Melton., *Meth. Enzymol.* 155:397-415, 1987) using the SP6 transcription of the pCS2-hND2, pCS2-hND1, pCS2-mND2, and pCS2MT-mND2. The capped RNA was phenol/chloroform extracted followed by separation of unincorporated nucleotides using a G-50 spin column. Approximately 350 pg or capped RNA was injected into one cell of 2-cell stage albino *Xenopus laevis* embryo in a volume of approximately 5 nl, as described previously (Turner and Weintraub, 1994). Embryos were allowed to develop in 0.1X modified Barth's saline (MBS) and staged according to Nieuwkoop and Faber (Nieuwkoop, P.D. and J. Faber, "Normal Table of *Xenopus laevis*," North-Holland Publishing Co., Amsterdam, The Netherlands, 1967). Embryos were fixed in MEMFA for 2 hours at room temperature and stored in methanol. Embryos were hydrated through a graded series of methanol/PBS solutions and prepared for immunohistochemistry as described (Turner and Weintraub, 1994). The embryos were stained with an anti-NCAM antibody (Balak et al. *Develop. Biol.* 119:540-550, 1987) diluted 1:500 (gift of Urs Rutishauser) followed by a goat anti-rabbit alkaline phosphatase conjugated secondary antibody, or stained with the monoclonal anti-myc tag 9e10 antibody. Presence of the antibody was visualized by NBT/BCIP color reaction according to protocol provided (Gibco).

Antibodies to *Xenopus* N-CAM, a neural adhesion molecule, anti-Myc (to detect the exogenous protein tag), and immunostaining techniques were used to evaluate phenotypic expression of the neuronal marker (and control) gene during the subsequent developmental stages of the microinjected embryos. Remarkably, an evaluation of over 130 embryos that were injected with *neuroD1* RNA showed a striking increase in ectopic expression of N-CAM on the microinjected side of the embryo (i.e., Myc⁺), as judged by increased immunostaining. The increased staining

was observed in the region from which neural crest cells normally migrate. It is considered likely that ectopic expression (or over-expression) of *neuroD1* caused neural crest stem cells to follow a neurogenic cell fate. Outside the neural tube, the ectopic immunostaining was observed in the facio-cranial region and epidermal layer, and in some cases the stained cells were in the ventral region of the embryo far from the neural tube. The immunostained cells not only expressed N-CAM ectopically, but displayed a morphological phenotype of neuronal cells. At high magnification, the N-CAM expressing cells exhibited typical neuronal processes reminiscent of axonal processes.

To confirm that the ectopic N-CAM expression resulted from a direct effect on the presumptive epidermal cells and not from aberrant neural cell migration into the lateral and ventral epidermis, *neuroD1* RNA was injected into the top tier of 32-cell stage embryos, in order to target the injection into cells destined to become epidermis. N-CAM staining was observed in the lateral and ventral epidermis without any noticeable effect on the endogenous nervous system, indicating that the staining of N-CAM in the epidermis represents the conversion of epidermal cell fate into neuronal cell fate.

Ectopic generation of neurons by *neuroD1* was confirmed with other neural specific markers, such as neural-specific class II β -tubulin (Richter et al., *Proc. Natl. Acad. Sci. USA* 85:8066, 1988), acetylated I-tubulin (Piperno and Fuller, *J. Cell. Biol.* 101:2085, 1985), tanabin (Hemmati-Brinvarlou et al., *Neuron* 9:417, 1992), neurofilament(NF)-M (Szaro et al., *J. Comp. Neurol.* 273:344, 1988), and Xen-1,2 (Ruiz i Altaba, *Development* 115:67, 1992). The embryos were subjected to immunochemistry as described by Turner and Weintraub (*Genes Dev.* 8:1434, 1994, which is incorporated by reference herein) using primary antibodies detected with alkaline phosphatase-conjugated goat anti-mouse or anti-rabbit antibodies diluted to 1:2000 (Boehringer-Mannheim). Anti-acetylated alpha-tubulin was diluted 1:2000. Anti-Xen-1 was diluted 1:1. Anti-NF-M was diluted 1:2000. Embryos stained for NF-M were fixed in Dent's fixative (20% dimethylsulfoxide/80% methanol) and cleared in 2:1 benzyl benzoate/benzyl alcohol as described by Dent et al. (*Development* 105:61, 1989, which is incorporated by reference herein). *In situ* hybridization of embryos was carried out essentially as described by Harland (in *Methods in Cell Biology*, B.K. Kay, H.J. Pend, eds., Academic Press, New York, NY, Vol. 36, pp. 675-685, 1991, which is incorporated by reference herein) as modified by Turner and Weintraub (*ibid.*). *In situ* hybridization with β -tubulin

without RNase treatment can also detect tubulin expression in the ciliated epidermal cells. All of these markers displayed ectopic staining on the *neuroDI* RNA injected side. Injection of *neuroDI* mRNA into vegetal cells led to no ectopic expression of neural markers except in one embryo that showed internal N-CAM staining in the
5 trunk region, suggesting the absence of cofactors or the presence of inhibitors in vegetal cells. However, the one embryo that showed ectopic neurons in the internal organ tissue suggests that it may be possible to convert non-ectodermal lineage cells into neurons under certain conditions.

The embryos were also stained with markers that detect Rohon-Beard cells
10 (cells in which *neuroDI* is normally expressed). Immunostaining using the method described above for Rohon-Beard cell-specific markers such as HNK-1 (Nordlander, *Dev. Brain Res.* 50:147, 1989, which is incorporated by reference herein) at a dilution of 1:1, Islet-1 (Ericson et al., *Science* 256:1555, 1992 and Korzh et al., *Development* 118:417, 1993) at a dilution of 1:500, and *in situ* hybridization as described above
15 with shaker-1 (Ribera et al., *J. Neurosci.* 13:4988, 1993) showed more cells staining on the injected side of the embryos.

The combined results support the notion that ectopic expression of *neuroDI* induced differentiation of neuronal cells from cells that, without *neuroDI* microinjection, would have given rise to non-neuronal cells. In summary, these
20 experiments support the notion that ectopic *neuroDI* expression can be used to convert a non-neuronal cell (i.e., uncommitted neural crest cells and epidermal epithelial basal stem cells) into a neuron. These findings offer for the first time the potential for gene therapy to induce neuron formation in injured neural tissues.

Interesting morphological abnormalities were observed in the microinjected
25 embryos. In many cases the eye on the microinjected side of the embryo failed to develop. In other embryos, the spinal cord on the microinjected side of the embryo failed to develop properly, and the tissues were strongly immunopositive when stained with anti-N-CAM. In addition, at the mid-neurula stage many microinjected embryos exhibited an increase in cell mass in the cranial region of the embryo from which (in a
30 normal embryo) the neural crest cells and their derivatives (i.e., cranial ganglionic cells) would migrate. The observed cranial bulge exhibited strong immunostaining with antibodies specific for N-CAM. These results were interpreted to mean that morphological changes in the eye, neural crest, and spinal cord resulted from premature neural differentiation which altered the migration of neural and neural crest
35 precursor cells.

NeuroD1-injected embryos were also assayed for alteration in the expression of Xtwist, the *Xenopus* homolog of *Drosophila* twist, to determine whether *neuroD1* converted non-neuronal components of neural crest cells into the neural lineage. In wild-type embryos, Xtwist is strongly expressed in the non-neuronal population cephalic neural crest cells that give rise to the connective tissue and skeleton of the head. *NeuroD1*-injected embryos were completely missing Xtwist expression in the migrating cranial neural crest cells on the injected side. The failure to generate sufficient cranial mesenchymal neural crest precursors in *neuroD1*-injected embryos was also observed morphologically, since many of the injected embryos exhibited poor branchial arch development in the head. Furthermore, the increased mass of cells in the cephalic region stained very strongly for N-CAM, β -tubulin, and Xen-1, indicating that these cells were neural in character.

The converse experiment in which frog embryos were injected with Xtwist mRNA showed that ectopic expression of Xtwist significantly decreased *neuroD1* expression on the injected side. Thus, two members of the bHLH family, *neuroD1* and Xtwist, may compete for defining the identity of different cell types derived from the neural crest. In the *neuroD1*-injected embryos, exogenous *neuroD1* may induce premigratory neural crest to differentiate into neurons *in situ*, and consequently they fail to migrate to their normal positions.

The effect of introduction of exogenous *neuroD1* on the fate of cells that normally express *neuroD1*, such as cranial ganglia, eye, otic vesicle, olfactory organs, and primary neurons, and on other CNS cells that normally do not express *neuroD1*, was determined by staining for differentiation markers. When the cranial region of the embryo was severely affected by ectopic *neuroD1*, the injected side of the embryos displayed either small or no eyes in addition to poorly organized brains, otic vesicles, and olfactory organs. Moreover, as the embryos grew, the spinal cord showed retarded growth, remaining thinner and shorter on the *neuroD1*-injected side.

N-CAM staining in the normal embryo at early stages was not uniform throughout the entire neural plate, but rather was more prominent in the medial region of the neural plate. Injected embryos analyzed for N-CAM expression showed that the neural plate on the injected side of the early stage embryos was stained more intensely and more laterally. The increase in N-CAM staining was not associated with any lateral expansion of the neural plate as assayed by visual inspection and staining with the epidermal marker EpA. This was in contrast to what has been observed with XASH-3 injection that causes neural plate expansion. These observations suggest

that the first effects of *neuroD1* are to cause neuronal precursors in the neural plate to differentiate prematurely.

To determine whether *neuroD1* caused neuronal precursors to differentiate prematurely, injected embryos were stained using two neuronal markers that are expressed in differentiated neurons, neural specific β -tubulin and tanabin. *In situ* hybridization for β -tubulin and tanabin was carried out as described above. Over-expression of *neuroD1* dramatically increased the β -tubulin signals in the region of the neural plate containing both motor neurons and Rohon-Beard cells at stage 14. The earliest ectopic β -tubulin positive cells on the injected side were observed at the end of gastrulation when the control side did not yet show any β -tubulin positive cells. Tanabin was also expressed in more cells in the spinal cord in the *neuroD1* injected side of the embryos at stage 14. These results suggest that *neuroD1* can cause premature differentiation of the neural precursors into differentiated neurons. This is a powerful indication that, when ectopically expressed or over-expressed, *neuroD1* can differentiate mitotic cells into non-dividing mature neurons.

To determine if *neuroD2* also was capable of inducing ectopic neuronal development in the frog, mouse *neuroD2* RNA was injected into one side of a two cell *X. laevis* embryo, the uninjected side serving as a control. The *neuroD2* mRNA was made from pCS2-MTmND2, an expression vector that was constructed as follows. Expression vectors were made in the pCS2+ or pCS2+MT (Turner, D.L. and H. Weintraub, *Genes & Dev.* 8:1434-1447, 1994), both contain the simian CMV promoter and the MT contains six copies of the myc epitope recognized by the 9e10 monoclonal antibody (ATCC:CRL1729) cloned in-frame upstream of the insert. The 1.75 kb full length human *neuroD1* cDNA (Tamimi et al., *Genomics* 34: 418-421, 1996) from plasmid phcnd1-17a was cloned into the EcoRI site to make pCS2-hND1-17s (hereafter referred to as pCS2-hND1). The 1.53 kb genomic region containing the entire coding sequence of the human *neuroD2* gene (described in Example 11) was cloned into the StuI-XbaI site to make pCS2-hND2-14B1 (hereafter referred to as pCS2-hND2). The mouse 1.95 kb *neuroD2* cDNA was cloned into the EcoRI-XhoI sites to make pCS2-mND2-1.1.1 (hereafter referred to as pCS2-mND2). For the *myc*-tagged construct, a synthetic oligonucleotide mediated mutagenesis was used to introduce an EcoRI site adjacent to the initial ATG codon to result in the *myc*-tag and *neuroD2* coding regions being in-frame to make pCS2MT-mND2.

When injected into *Xenopus laevis*, mouse *neuroD2* mRNA was able to induce ectopic neuronal development as determined by immunohistochemistry with an

anti-NCAM antibody. An anti-myc tag antibody, 9E10, was used to confirm that most ectodermal cells on the injected side of the frog expressed the myc-tagged mouse *neuroD2* and approximately 80-90% of injected embryos stained positively with either the anti-myc or anti-NCAM antibodies. Injection of RNA encoding the human *neuroD2* gene resulted in an ectopic neuronal phenotype similar to that seen with *Xenopus neuroD1* and murine *neuroD2*. This demonstrates that both *neuroD1* and *neuroD2* can regulate the formation of neurons and that the human and mouse *neuroD2* proteins are capable of functioning in the developing *Xenopus* embryo.

Developmental expression patterns suggest two distinct sub-families of neurogenic bHLH genes. *MATH1* and *neuroD3* share similarity in the bHLH region and have similar temporal expression patterns, with RNA expression detected around embryonic day 10, but not persisting in the mature nervous system. *MATH-1* RNA was localized to the dorsal neural tube in 10.5-11.5 day embryos, but by birth was present only in the external granule cell layer of the cerebellum, the progenitors of the cerebellar granule cell layer (Akazawa et al., 1995). In contrast, the *neuroD1*, *neuroD2*, and *MATH2/NEX-1* genes are expressed in both differentiating and mature neurons. Northern analysis demonstrated that *neuroD2* expression begins around embryonic day 11 and continues through day 16, the latest embryonic time point tested. *NeuroD2* was detected in the brain of neonates as well as adult mice, with relatively equal abundance in both the cerebellum and cortex. Similar to *neuroD2*, the CNS expression of *neuroD1* persists postnatally, as well as does its expression in the beta cells of the pancreas (Naya et al., 1995). Northern blot analysis indicated that *neuroD1* expression in the adult mouse brain is most abundant in the cerebellum with lower levels in the cerebral cortex and brain stem. *NEX-1/MATH-2* gene expression is reported to occur by embryonic day 11.5 and at embryonic day 15.5 its expression is limited to the intermediate zone adjacent to the mitotically active ventricular zone, suggesting that *NEX-1/MATH2* is expressed primarily in the newly differentiating neurons at this stage (Bartholoma, A. and K. A. Nave, 1994; Shimizu et al., 1995). In mature brain, *NEX-1/MATH-2* is expressed in neurons comprising the hippocampus, subsets of cortical neurons, and post migratory cerebellar granule cells, but the reports disagree on whether this gene is expressed in the dentate gyrus of the hippocampus. It is interesting to note that the Northern analysis of *MATH2* expression reported by Shimizu et al. (1995) shows high levels in the cerebral cortex and low levels in the cerebellum, the opposite of the expression pattern seen for *neuroD1*, suggesting that these genes may also have significant differences in relative abundance in specific

regions of the nervous system. Therefore, it appears that *MATH-1* and *neuroD3* are expressed early in nervous system development and may have a role in either determining or expanding a population of neuronal precursors, whereas the persistent expression of *neuroD1*, *neuroD2* and *NEX-1/MATH-2* suggest a role in initiating and maintaining expression of genes related to neuronal differentiation.

Kume et al. (*Biochem. Biophys. Res. Comm.* 219:526-530, 1996) have reported the cloning of a helix-loop-helix gene from rat brain using a strategy designed to identify genes that are expressed during tetanic stimulation of hippocampal neurons in a model of long-term-potentiation. The gene they describe, *KW8*, is the rat homolog of the mouse and human *neuroD2* gene described here. Kume et al. also describe expression in the adult brain, including the hippocampus. Subsequently, Yasunami et al. (*Biophys. Res. Comm.* 220:754-758, 1996) reported the mouse NDRF gene, which is nearly identical to *neuroD2* and demonstrates a similar expression pattern in adult brain by *in situ* hybridization.

While expression of either *neuroD1* or *neuroD2* in *Xenopus laevis* embryos resulted in ectopic neuronal development, it is interesting to note that neither *neuroD1* nor *neuroD2* was capable of converting all cell types in which it was present into neurons. As in the case of *neuroD1*, the ectopic neurons induced by *neuroD2* were confined to a subpopulation of ectodermal cells, as indicated by the spotty NCAM positive staining pattern. The apparent restricted activity of the *neuroD* proteins to a subset of cells derived from the ectoderm suggests that other factors may regulate their activity, such as the *notch* pathway that mediates lateral inhibition during *Drosophila* neurogenesis.

While the induction of ectopic neurogenesis by both *neuroD1* and *neuroD2* in *Xenopus* embryos suggests a similar function, the developmental expression patterns and *in vitro* transfection experiments indicate that the family members may serve both overlapping and distinct functions. Previous studies have demonstrated that *neuroD/beta2* and *NEX-1/MATH2* can bind the core CANNTG sequence of an E-box as a heterodimer with an E-protein and activate transcription.

In the work presented here, it is shown that both *neuroD1* and *neuroD2* can activate a construct containing multimerized E-boxes. They also activate a construct driven by a genomic fragment from the *neuroD2* gene that presumably contains regulatory regions for *neuroD2*, and the temporal expression pattern of *neuroD1* and *neuroD2* proteins in embryogenesis and P19 differentiation suggests a model in which *neuroD1* may activate *neuroD2* expression during development. Most important,

however, is the demonstration that neuroD1 and neuroD2 have different capacities to activate a construct driven by the core regulatory sequences of the *GAP-43* gene, demonstrating that the highly related neuroD1 and neuroD2 proteins are capable of regulating specific subsets of genes. This promoter contains several E-boxes and it remains to be determined if neuroD2 directly binds to these sites.

In the bHLH region, neuroD1 and neuroD2 differ by only 2 amino acids and it would be anticipated that they recognize the same core binding sequences. Therefore, the differential regulation of transcriptional activity may be determined independently of DNA binding. The amino acid following the histidine in the junction region of the basic region is a glycine in neuroD1, NEX-1/MATH2, and MATH1, an aspartate in neuroD2, and an asparagine in neuroD3. This residue is positioned at the same site as the lysine residue in the myogenic bHLH proteins that has been shown to be one of the critical for myogenic activity (Davis et al., *Cell* 60:733-746, 1990; Davis, R. L. and H. Weintraub, *Science* 256:1027-1030, 1992; Weintraub et al., *Genes & Dev.* 5:1377-1386, 1991). In this case, it has been postulated to be a site of potential interaction with co-activator factors that regulate transcriptional activity. If the neuroD proteins have a similar mechanism for exerting their regulatory activities, it is possible that amino acid variability in this amino acid mediates different target specificities. Alternatively, the more divergent amino- and carboxyterminal regions could confer regulation by interaction with other activators or repressors.

The different expression patterns in the mature nervous system and the subtle differences in target genes is similar to myogenic bHLH proteins. In mature muscle, *MyoD* is expressed in fast muscle fibers and *myogenin* in slow fibers (Asakura et al., *Develop. Biol.* 171:386-398, 1995; Hughes et al., *Development* 118:1137-1147, 1993) and transfection studies demonstrate that sequences adjacent to the core E-box sequence can differentially regulate the ability of MyoD and myogenin to function as transcriptional activators (Asakura et al., *Molec. & Cell. Biol.* 13:7153-7162, 1993), presumably by interaction of other regulatory factors with the non-bHLH regions of MyoD and myogenin. For the *neuroD*-related genes, the partially overlapping expression patterns and partially overlapping target genes suggest that they may act in a combinatorial fashion to directly regulate overlapping subsets of genes and thereby confer specific neuronal phenotypes. In this model, it is possible that a small family of neuroD-related transcription factors acts to establish the identity of a limited number of neuronal sub-types and that local inductive events influence the generation of a higher complexity. Alternatively, it is possible that many additional members of this

sub-family are yet to be identified and they may act to directly determine specific neuronal attributes.

EXAMPLE 11

Genomic clones of human *neuroD1*, *neuroD2* and *neuroD3* and mouse *neuroD3*.

5 Genomic clones encoding human *neuroD1* were obtained by probing a human fibroblast genomic library with the mouse *neuroD1* cDNA. Host *E. coli* strain LE392 (New England Biolabs) were grown in LB + 10 mM MgSO₄, 0.2% maltose overnight at 37°C. The cells were harvested and resuspended in 10 mM MgSO₄ to a final OD₆₀₀ of 2. The resuspended cells were used as hosts for phage infection. The
10 optimal volume of phage stock for use in this screening was determined by using serial dilutions of the phage stock of a human fibroblast genomic library in lambda FIX II (Stratagene®) to infect LE392 cells (New England Biolabs). To obtain approximately 50,000 plaques per plate, a 2.5 µl aliquot of the phage stock was used to infect 600 µl of the resuspended LE392 cells. The cells were incubated with the
15 phage for 15 minutes at 37°C, after which the cells were mixed with 6.5 ml of top agar warmed to 50°C. The top agar was plated on solid LB, and incubated overnight at 37°C. A total of 22 15-cm plates were prepared in this manner.

Duplicate plaque lifts were prepared. A first set of Hybond membranes (Amersham) were placed onto the plates and allowed to sit for 2 minutes. The initial
20 membranes were removed and the duplicate membranes were laid on the plates for 4 minutes. The membranes were allowed to air dry; then the phage were denatured in 0.5 M NaOH, 1.5 M NaCl for 7 minutes. The membranes were neutralized with two washes in neutralization buffer (1.5M NaCl, 0.5 M Tris, pH 7.2). After neutralization, the membranes were crosslinked by exposure to UV. A 1 kb Eco RI-
25 Hind III fragment containing murine *neuroD1* coding sequences was random primed using the Random Priming Kit (Boehringer Mannheim) according to the manufacturer's instructions. Membranes were prepared for hybridization by placing six membranes in 10 ml of FBI hybridization buffer [100 g polyethylene glycol 800, 350 ml 20% SDS, 75 ml 20X SSPE; add water to a final volume of one liter] and
30 incubating the membranes at 65°C for 10 minutes. After 10 minutes, denatured salmon sperm DNA was added to a final concentration of 10 µg/ml and denatured probe was added to a final concentration of 0.25-0.5 x 10⁷ cpm/ml. The membranes were hybridized at 65°C for a period of 8 hours to overnight. After incubation, the excess probe was removed, and the membranes were washed first in 2 X SSC, 0.1%
35 SDS for 30 minutes at 50°C. The first wash was followed by a final wash in 0.1 X

SSC, 0.1% SDS for 30 minutes at 55°C (moderate stringency). Autoradiographs of the membranes were prepared. The first screen identified 55 putative positive plaques. Thirty-one of the plaques were subjected to a secondary screen using the method essentially set forth above. Ten positive clones were identified and subjected
5 to a tertiary screen as described above. Eight positive clones were identified after the tertiary screen. Of these eight clones, three (14B1, 9F1 and 20A1) were chosen for further analysis. Clones 14B1 and 20A1 were deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 USA, on November 1, 1995, under accession numbers 69943 and 69942, respectively.

10 Phage DNA was prepared from clones 14B1, 9F1, and 20A1. The 14B1 and 20A1 phage DNA were digested with Pst I to isolate the 1.2 kb and 1.6 kb fragments, respectively, that hybridized to the mouse *neuroD1* probe. The 9F1 phage DNA was digested with Eco RI and SacI to obtain an approximately 2.2 kb fragment that hybridizes with the mouse *neuroD1* probe. The fragments were each subcloned into
15 plasmid BLUESCRIPT SK (Stratagene) that had been linearized with the appropriate restriction enzyme(s). The fragments were sequenced using Sequenase Version 2.0 (US Biochemical) and the following primers: the universal primer M13-21, the T7 primer, and the T3 primer.

Sequence analysis of clones 9F1 (SEQ ID NOS:8 and 9), and 14B1 (SEQ ID
20 NOS:10 and 11) showed a high similarity between the mouse and human coding sequences at both the amino acid and nucleotide level. In addition, while clones 9F1 and 14B1 shared 100% identity in the HLH region at the amino acid level (i.e., residues 117-156 in SEQ ID NO:9 and residues 137-176 in SEQ ID NO:11), they diverged in the amino-terminal of the bHLH. This finding strongly suggests that
25 14B1 is a member of the *neuroD* family of genes. Sequence analysis demonstrates that clone 9F1 has a high degree of homology throughout the sequence region that spans the translation start site to the end of the bHLH region. The 9F1 clone has 100% identity to mouse *neuroD1* in the HLH region (i.e., residues 117-156 in SEQ ID NO:9 and residues 117-156 in SEQ ID NO:2), and an overall identity of
30 94%. The 14B1 clone also has 100% identity to the HLH region (i.e., residues 137-176 in SEQ ID NO:11 and residues 117-156 in SEQ ID NO:2), but only 40% identity to 9F1 and 39% identity to mouse *neuroD1* in the amino-terminal region. This demonstrates that 9F1 is the human homolog of mouse *neuroD1*, whereas the strong conservation of the *neuroD* HLH identifies 14B1 as another member of the
35 *neuroD* HLH subfamily. Human clone 9F1 (represented by SEQ ID NOS: 8 and 9) is

referred to as human *neuroD1*. Human clone 14B1 is referred to as *neuroD2* (SEQ ID NOS:10 and 11, and human clone 20A1 is referred to as *neuroD3* (SEQ ID NOS:12 and 13).

5 A fragment of the human *neuroD2* gene was used to screen both a mouse genomic library and an embryonic day 16 mouse cDNA library. An 800 bp Hind III-Eag I fragment from the *neuroD2* sequences from clone 14B1 was random primed with ³²P, and used to screen a 16-day mouse embryo cDNA library essentially as described previously. Filters were prehybridized in FBI hybridization buffer (see above) at 50°C for 10 minutes. After prehybridization, denatured salmon sperm DNA
10 was added to a final concentration of 10 µg/ml; denatured probe was added to a final concentration of one million cpm/ml. The filters were hybridized at 50°C overnight. After incubation, excess probe was removed, and the filters was washed first in 2 X SSC, 0.1% SDS for 30 minutes at 60°C. Genome clones were obtained and characterized. Five independent cDNAs were mapped by restriction endonucleases
15 and demonstrated identical restriction sites and sequence. One clone, designated 1.1.1, contained 1.46 kb of murine *neuroD2* cDNA as an Eco RI-Hind III insert. The nucleotide sequence and deduced amino acid sequences are shown in SEQ ID NOS:16 and 17, respectively. A comparison with the corresponding mouse genomic sequence demonstrated that the entire coding region of *neuroD2* is contained in the
20 second exon.

The mouse *neuroD2* cDNA sequence indicated a predicted protein of 382 amino acids that differs from the major open reading frame in the human *neuroD2* gene at only 9 residues, all in the aminoterminal portion of the protein. The human *neuroD2* protein was found to have 98% similarity to *neuroD1* and MATH2 in the
25 bHLH region and 90% similarity in the 30 amino acids immediately carboxyterminal to the bHLH region. Similar to *neuroD1* and MATH2, *neuroD2* contains an aminoterminal region rich in glutamate residues that may constitute an acidic activation domain, and has other regions of similarity to *neuroD1* throughout the protein.

30 Mouse *neuroD3* was obtained by screening a 129SV mouse genomic library cloned in lambda-Dash II (Stratagene®), using a labeled Pst-Pst genomic fragment containing the human *neuroD* coding sequence using conditions essentially as described above for selecting mouse *neuroD2*, with the exception that the prehybridization and hybridization were carried out at 55°C and the final wash was
35 carried out at 50°C

Since all identified members of the family of genes related to *neuroD1* are known to have their entire coding sequence in a single exon, the major open reading frame (ORF) encoded in the genomic DNA from human and mouse *neuroD3* were determined (SEQ ID NO:12 and SEQ ID NO:21, respectively). The predicted amino acid sequences of the mouse and human *neuroD3* proteins are based on the major ORF in the corresponding genomic DNAs, since cDNAs have not been cloned for these genes. The genomic sequence of mouse *neuroD3* contains a major ORF of 244 amino acids and the human *neuroD3* gene an ORF of 237 amino acids that differs from the predicted mouse protein at 26 positions. The entire coding region of other *neuroD* family members is contained within a single exon, and therefore it is possible that the ORF in the *neuroD3* genomic DNA represents the entire coding region, a notion supported by the conservation between mouse and human that extends to the stop codon. The major ORF predicts a smaller protein than related *neuroD* family members, and lacks the acidic rich aminoterminal region. The bHLH region has some elements of the loop that are similar to MATH1, but the overall level of homology in the bHLH region is closer to the *neuroD*-related genes. In contrast to *neuroD2*, the *neuroD3* protein does not contain significant regions of homology to *neuroD1* or MATH2/NEX-1 outside of the bHLH region and does not have an aminoterminal region rich in glutamates or acidic amino acids.

The Genbank accession numbers are: human *neuroD2*, U58681; mouse *neuroD2*, U58471; human *neuroD3*, U63842; mouse *neuroD3*, U63841.

EXAMPLE 12

Chromosome mapping of human *neuroD1* clones.

FISH karyotyping was performed on fixed metaphase spreads of the microcell hybrids essentially as described (Trask et al., *Am. J. Hum. Genet.* 48:1-15, 1991; and Brandriff et al., *Genomics* 10:75-82, 1991; which are incorporated by reference herein in their entirety). *NeuroD1* sequences were detected using the 9F1 or 20A1 phage DNA as probes labeled using digoxigenin-dUTP (Boehringer Mannheim) according to the manufacturer's instructions. Phage DNA was biotinylated by random priming (Gibco/BRL BioNick Kit) and hybridized *in situ* to denatured metaphase chromosome spreads for 24-48 hours. Probes were detected with rhodamine-conjugated antibodies to digoxigenin, and chromosomes were counterstained with DAPI (Sigma). Signals were viewed through a fluorescence microscope and photographs were taken with color slide film. FISH analysis indicated clone 9F1 maps to human chromosome 2q, and clone 20A1 maps to human chromosome 5.

Chromosome mapping was also carried out on a human/rodent somatic cell hybrid panel (National Institute of General Medical Sciences, Camden, NJ). This panel consists of DNA isolated from 24 human/rodent somatic cell hybrids retaining one human chromosome. For one set of experiments, the panel of DNA's were
5 digested with Eco RI and electrophoresed on an agarose gel. The DNA was transferred to Hybond-N membranes (Amersham). A random primed (Boehringer Mannheim) 4 kb Eco RI-Sac I fragment of clone 9F1 was prepared. The filter was prehybridized in 10 ml of FBI hybridization buffer (see above) at 65°C for 10 minutes. After prehybridization, denatured salmon sperm DNA was added to a final
10 concentration of 10 µg/ml; denatured probe was added to a final concentration of one million cpm/ml. The filter was hybridized at 65°C for a period of 8 hours to overnight. After incubation, excess probe was removed, and the filter was washed first in 2 X SSC, 0.1% SDS for 30 minutes at 65°C. The first wash was followed by a final stringent wash in 0.1 X SSC, 0.1% SDS for 30 minutes at 65°C. An
15 autoradiograph of the filter was prepared. Autoradiographs confirmed the FISH mapping results.

In the second experiment, the panel was digested with Pst I, electrophoresed and transferred essentially as described above. A random-primed (Boehringer Mannheim) 1.6 kb Pst I fragment of clone 20A1 was prepared. The membrane was
20 prehybridized, hybridized with the 20A1 probe and washed as described above. Autoradiographs of the Southern filter showed that 20A1 mapped to human chromosome 5 and confirmed the FISH mapping results. After autoradiography, the 20A1-probed membrane was stripped by a wash in 0.5 M NaOH, 1.5 M NaCl. The membrane was neutralized in 0.5 M Tris-HCl (pH 7.4), 1.5 M NaCl. The filter was
25 washed in 0.1 X SSC before prehybridization. A random-primed (Boehringer Mannheim) 1.2 kb Pst I fragment of clone 14B1 was prepared. The washed membrane was prehybridized and hybridized with the 14B1 probe as described above. After washing under the previously described conditions, the membrane was autoradiographed. Autoradiographs demonstrated that clone 14B1 mapped to
30 chromosome 17.

EXAMPLE 13

Human *neuroD1* complementary DNA.

To obtain a human *neuroD1* cDNA, one million plaque forming units (pfu) were plated onto twenty LB + 10 mM MgSO₄ (150 mm) plates using the Stratagene
35 human cDNA library in Lambda ZAP II in the bacterial strain XL-1 Blue (Stratagene).

Plating and membrane lifts were performed using standard methods, as described in Example 11. After UV cross-linking, the membranes were pre-hybridized in an aqueous hybridization solution (1% bovine serum albumin, 1 mM EDTA, 0.5 M Na₂HPO₄ (pH 7.4), 7% SDS) at 50°C for two hours.

5 The mouse *neuroD1* cDNA insert was prepared by digesting the pKS+ m7a RX plasmid with Eco RI and Xho I, and isolating the fragment containing the cDNA by electroelution. A probe was made with the cDNA containing fragment by random primed synthesis with random hexanucleotides, dGTP, dATP, dTTP, alpha-³²P-labeled dCTP, and Klenow in a buffered solution (25 mM Tris (pH6.9), 50mM
10 KCl, 5mM MgCl₂, 1mM DTT). The probe was purified from the unincorporated nucleotides on a G-50 Sepharose® column. The purified probe was heat denatured at 90°C for 3 minutes.

After prehybridization, the denatured probe was added to the membranes in hybridization solution. The membranes were hybridized for 24 hours at 50°C. Excess
15 probe was removed from the membranes, and the membranes were washed in 0.1 X SSC, 0.1% SDS for 20 minutes at 50°C. The wash solution was changed five times. The membranes were blotted dry and covered with plastic film before being subjected to autoradiography. Autoradiography of the filters identified 68 positive clones. The clones were plaque-purified and rescreened to obtain 40 pure, positive clones. The
20 positive clones were screened with a random-primed Pst I fragment from clone 9F1 (human *neuroD1*). Twelve positive clones that hybridized with the human *neuroD1* genomic probe were isolated.

The plasmid vector containing cDNA insert was excised *in vivo* from the lambda phage clone according to the Stratagene methodology. Briefly, eluted phage
25 and XL-1 Blue cells (200 microliters of OD 600=1) were mixed with R408 helper phage provided by Stratagene for 15 minutes at 37°C. Five milliliters of rich bacterial growth media (2 X YT, see Sambrook et al., *ibid.*) was added, and the cultures were incubated for 3 hours at 37°C. The tubes were heated at 70°C for 20 minutes and spun for 5 minutes at 4,000 X g. After centrifugation, 200 microliters of supernatant
30 were added to the same volume of XL-1 Blue cells (OD=1), and the mixture was incubated for 15 minutes at 37°C, after which the bacterial cells were plated onto LB plates containing 50 mg/ml ampicillin. Each colony was picked and grown for sequencing template preparation. The clones were sequenced and compared to the human genomic sequence. A full length cDNA encoding human *neuroD1* that was
35 identical to the 9F1 *neuroD1* genomic sequence was obtained and designated HC2A.

The nucleotide and deduced amino acid sequences are shown in SEQ ID NOS: 14 and 15, respectively. Clone HC2A was deposited at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD 20852 USA, on November 1, 1995, under accession number 69944.

5 Using a random-primed radiolabeled antisense probe to the mouse *neuroD2* (Boehringer Mannheim), the expression pattern was determined using Northern analysis. Filters containing murine RNA from the brain and spinal cords of embryonic through adult mice were probed at high stringency and washed in 0.1 X SSC, 0.1% SDS at 65°C. Northern analysis showed *neuroD2* expression in the brain and spinal
10 cords of mice from embryonic day 12.5 through adult.

Experiments were conducted also to isolate a cDNA corresponding to mouse *neuroD3* mRNA. Using procedures similar to those described above, a random-primed 1.1 kb Pst I fragment from human *neuroD3* clone 20A1 was prepared and used to screen mouse embryo and newborn mouse brain libraries. For unknown
15 reasons, no positive clones were obtained. Likewise, attempts to clone human *neuroD3* cDNA have been unsuccessful. The difficulty in obtaining *neuroD3* cDNA may be secondary to instability of the construct in the library, since deletions in the genomic DNA were common during amplification.

EXAMPLE 14

20 Construction of knock-out mice

Knock-out mice in which the murine *neuroD1* coding sequence was replaced with the 9-galactosidase gene and the neomycin resistance gene (neo) were generated i) to assess the consequences of eliminating the murine *neuroD1* protein during mouse development and ii) to permit examination of the expression pattern of *neuroD1* in
25 embryonic mice. Genomic *neuroD1* sequences used for these knock-out mice were obtained from the 129/Sv mice so that the homologous recombination could take place in a congenic background in 129/Sv mouse embryonic stem cells. Several murine *neuroD1* genomic clones were isolated from a genomic library prepared from 129/Sv mice (Zhuang et al., *Cell* 79:875-884, 1994; which is incorporated herein by reference in its entirety) using the Bam HI-Not I *neuroD1* cDNA containing fragment
30 of pSK+1-83 (Example 2) as a random-primed probe essentially as described in Example 11. Plasmid pPNT (Tybulewicz et al., *Cell* 65:1153-1163, 1991; which is incorporated herein by reference in its entirety) containing the neomycin resistance gene (neo; a positive selection marker) and the *Herpes simplex virus thymidine kinase* gene (*hsv-tk*; a negative selection marker) under the control of the PGK promoter
35

provided the vector backbone for the targeting construct. A 1.4 kb 5' murine *neuroD1* genomic fragment together with the 3 kb cytoplasmic β -galactosidase gene were inserted between the Eco RI and Xba I sites of the pPNT vector, and an 8 kb fragment containing the genomic 3' untranslated sequence of *neuroD1* was inserted into the vector backbone between into the Xho I and Not I sites.

To prepare an Eco RI-Xba I fragment containing *neuroD1* promoter sequences joined to the β -galactosidase gene, a 1.4 kb Eco RI(vector-derived)-Asp 718 fragment containing the 5' untranslated murine *neuroD1* genomic sequence was ligated to a Hind III-Xba I fragment containing the cytoplasmic β -galactosidase gene such that the Asp 718 and Hind III sites were destroyed. The resulting approximately 4.4 kb Eco RI-Xba I fragment, containing the 5' *neuroD1* genomic sequence (including the *neuroD1* promoter) and the β -galactosidase gene in the same transcriptional orientation, was inserted into Eco RI-Xba I linearized pPNT to yield the plasmid pPNT/5'+ β -gal. A *neuroD1* fragment containing 3' untranslated DNA was obtained from a murine *neuroD1* genomic clone that had been digested with Spe I and Not I(vector-derived) to yield an 8 kb fragment. To obtain a 5' Xho I site, the 8 kb fragment was inserted into Spe I-Not I linearized pBluescriptSK+ (Stratagene), and the resulting plasmid digested with Xho I and Not I to obtain the 8 kb *neuroD1* 3' genomic fragment. The Xho I-Not I fragment was inserted into Xho I-Not I linearized pPNT/5'+ β -gal to yield the *neuroD1* targeting vector. The final construct contained the 5' *neuroD1* fragment, the β -galactosidase gene, and the 3' genomic *neuroD1* fragment in the same orientation, and the *hsv-tk* and neomycin resistance genes in the opposite orientation.

The targeting construct was transfected by electroporation into mouse embryonic stem (ES) cells. A 129/Sv derived ES cell line, AK-7 described by Zhuang et al. (ibid.) was used for electroporation. These ES cells were routinely cultured on mitomycin C-treated (Sigma) SNL 76/7 cells (feeder cells) as described by McMahon and Bradley (*Cell* 62:1073-1085, 1990; which is incorporated herein by reference in its entirety) in culture medium containing high glucose DMEM supplemented with 15% fetal bovine serum (Hyclone) and 0.1 μ M β -mercaptoethanol. To prepare the targeting construct for transfection, 25 μ g of the targeting construct was linearized by digestion with Not I, phenol-chloroform extracted, and ethanol precipitated. The linearized vector was then electroporated into $1-2 \times 10^7$ AK-7 (ES) cells. The electroporated cells were seeded onto three 10-cm plates, with one plate receiving 50% of the electroporated cells and the remaining two plates each receiving 25% of

the electroporated cells. After 24 hours, G418 was added to each of the plates to a final concentration of 150 µg/ml. After an additional 24 hours, gancyclovir was added to a final concentration of 0.2 µM to the 50% plate and one of the 25% plates. The third plate containing 25% of the electroporated cells was subjected to only G418 selection to assess the efficiency of gancyclovir selection. The culture medium for each plate was changed every day for the first few days, and then changed as needed after selection had occurred. After 10 days of selection, a portion of each colony was picked microscopically with a drawn micropipette, and was directly analyzed by PCR as described by Joyner, et al. (*Nature* 338:153-156, 1989; which is incorporated herein by reference in its entirety). Briefly, PCR amplification was performed as described (Kogan et al., *New England J. Med.* 317:985-990, 1987; which is incorporated herein by reference in its entirety) using 40 cycles of 93°C for 30 seconds, 57°C for 30 seconds, and 65°C for 3 minutes. To detect the wild-type allele, primers JL34 and JL36 (SEQ ID NOS:18 and 19, respectively) were used in the PCR reaction, to detect the mutant *neuroD1* allele, primers JL34 and JL40 (SEQ ID NOS:18 and 20, respectively) were used in the PCR reaction. Positive colonies, identified by PCR, were subcloned into 4-well plates, expanded into 60 mm plates and frozen into 2-3 ampules.

Among the clones that were selected for both G418-resistance (positive selection for *neo* gene expression) and gancyclovir-resistance (negative selection for *hsv-tk* gene expression), 10% of the population contained correctly targeted integration of the vector into the murine *neuroD1* locus (an overall 10% targeting frequency). The negative selection provided 4-8 fold enrichment for homologous recombination events.

To generate chimeric mice, each positive clone was thawed and passaged once on feeder cells. The transfected cells were trypsinized into single cells, and blastocysts obtained from C57BL/6J mice were injected with approximately 15 cells. The injected blastocysts were then implanted into pseudopregnant mice (C57BL/6J x CBA). Four male chimeras arose from the injected blastocysts (AK-71, AK-72, AK-74 and AK-75). The male chimeras AK-71 and AK-72 gave germ-line transmission at a high rate as determined by the frequency of agouti coat color transmission to their offspring (F1) in a cross with C57BL/6J female mice. Since 50% of the agouti coat color offspring (F1) should represent heterozygous mutants, their genotypes were determined by Southern blot analysis. Briefly, genomic DNA prepared from tail biopsies was digested with Eco RI and probed with the 1.4 kb 5'

genomic sequence used to make the targeting construct. This probe detects a 4 kb Eco RI fragment from the wild-type allele and a 6.3 kb Eco RI fragment from the mutant allele. Therefore, a Southern analysis would show a single 4 kb band for a wild-type mouse, 4 kb and 6.3 kb fragments for a heterozygous mouse, and a single
5 6.3 kb band for a homozygous mutant mouse. The resulting offspring (F1) heterozygous (+/-) mice, were mated with sibling heterozygous mice to give rise to the homozygous (-/-) mutant mice.

To study *neuroDI* expression patterns in embryonic mice, chimeric mice or F1 heterozygous progeny from the chimera x C57B/6J mating were crossed with
10 C57B/6J. Litters resulting from these crosses were harvested from pregnant females and stained for β -galactosidase activity. The embryos were dissected away from all the extra-embryonic tissue and the yolk sac was reserved for DNA analysis. The embryos were fixed for one hour in a fixing solution (0.1 M phosphate buffer containing 0.2% glutaraldehyde, 2% formaldehyde, 5 mM EGTA (pH 7.3), 2 mM
15 MgCl₂). The fixing solution was removed by three thirty-minute rinses with rinse solution (0.1 M phosphate buffer (pH 7.3) containing 2 mM MgCl₂, 0.1% sodium deoxycholate, 0.2% NP-40). The fixed embryos were stained overnight in the dark in rinse solution containing 1 mg/ml X-gal, 5 mM sodium ferricyanide, 5 mM sodium ferrocyanide. After staining, the embryos were rinsed with PBS and stored in the
20 fixing solution before preparation for examination. Examination of stained tissue from fetal and postnatal mice heterozygous for the mutation confirmed the *neuroDI* expression pattern in neuronal cells demonstrated previously by *in situ* hybridization (Example 4), and also demonstrated *neuroDI* expression in the pancreas and gastrointestinal tract.

Blood glucose levels were detected using PRECISION QID blood glucose test strips and a PRECISION QID blood glucose sensor (Medisens Inc., Waltham, MA) according to the manufacturer's instruction. A tissue sample was taken for DNA analysis and the pups were fixed for further histological examination. Blood glucose levels in mice homozygous for the mutation (*neuroDI*) had blood glucose levels
30 between 2 and 3 times higher than the blood glucose level of wild-type mice. Heterozygous mutants exhibited similar blood glucose levels as wild-type mice. Mice that were homozygous for the mutation (lacking *neuroDI*) had diabetes as demonstrated by high blood glucose levels and died by day four; some homozygous mice died at birth.

EXAMPLE 15

*NeuroD1 expression and activity in PC12 and P19
embryonic carcinoma cells*

5 Murine PC12 pheochromacytoma cells differentiate into neurons in tissue culture in the presence of appropriate inducers, i.e., nerve growth factor. Neither induced nor non-induced murine PC12 cells expressed *neuroD1* transcripts, nor did control 3T3 fibroblasts produce detectable levels of *neuroD1* transcription products.

10 P19 cells are a well characterized mouse embryonic carcinoma cell line with the ability to differentiate into numerous cell types, including skeletal and cardiac muscle, or neurons and glia following treatment with dimethylsulfoxide (DMSO) or retinoic acid (RA) (Jones-Villeneuve et al., *Molec. & Cell. Biol.* 3:2271-2279, 1983), respectively. To determine whether P19 cells expressed endogenous *neuroD* genes during neuronal differentiation, RNA expression was analyzed for *neuroD1*, *neuroD2*, and *neuroD3* in both uninduced and induced P19 cells. To induce the formation of
15 neurons, P19 cells were cultured as aggregates in Petri dishes in the presence of retinoic acid for four days. The aggregates were then plated into tissue culture dishes in the absence of retinoic acid and neuronal differentiation occurred during a five day period, as evidenced by the formation of neurofilament positive process bearing cells.

NeuroD1 mRNA was most abundant after the cells were aggregated and
20 treated with RA for 4 days, and continued to be expressed at decreased levels during the period of neuronal differentiation. *NeuroD2* was not detected during the period of RA induction, but became abundant during the period of neuronal differentiation. Both *neuroD1* and *neuroD2* signals were modestly enhanced when the differentiated P19 cultures were grown in the presence of Ara-C which eliminates some of the non-
25 neuronal dividing cells, suggesting that the *neuroD1* and *neuroD2* genes are preferentially expressed in the post-mitotic cell population but further experiments will be necessary to prove this point. *NeuroD3* was first detected after two days of induction, and was most abundant after 4 days of induction), however, unlike *neuroD1*, *neuroD3* mRNA was not detected at the later, more differentiated, time
30 points. Therefore, the temporal expression pattern of *neuroD1*, *neuroD2*, and *neuroD3* in differentiating P19 cells was similar to that seen during embryonic development: a peak of *neuroD3* expression at the time of neuronal commitment and early neurogenesis, early and persistent expression of *neuroD1*, and slightly later and persistent expression of *neuroD2*. Hence, P19 cells are potentially useful in screening

assays for identifying inducers of neuroD1 expression that may stimulate nerve regeneration and differentiation of neural tumor cells.

NeuroD1 and *neuroD2* are both expressed in neurons and both can induce neurogenesis when expressed in frog embryos. To determine if they have the ability to activate similar target genes, expression vectors were constructed driving the human *neuroD1* or *neuroD2* coding regions from a simian cytomegalovirus promoter; these vectors are pCS2-hND1 and pCS2-hND2, whose construction is described in Example 10. The activity of neuroD1 and neuroD2 was assayed on reporter constructs co-transfected into P19 cells. Other members of the neuroD family have been shown to bind consensus E-box sequences *in vitro*. Gel shift assays have demonstrated that MATH-1 and NEX-1/MATH-2 bind the consensus E-box site CAGGTG as a heterodimer with the E47 protein, and activate the transcription of reporter constructs (Akazawa et al., 1995; Bartholoma, A. and K. A. Nave., 1994; Shimizu et al., 1995). *In vitro* gel shift assays demonstrated that neuroD1 and neuroD2 proteins can bind to an oligo containing the core E-box CACCTG as a heterodimer with an E-protein. Therefore, we tested the ability of neuroD1 and neuroD2 proteins to activate transcription of a simple reporter construct composed of a multimerized E-box with the same core sequence and the minimal promoter from the *thymidine kinase* gene driving *luciferase*, p4RTK-luc.

P19 cells to be transfected were cultured in minimal essential medium alpha supplemented with 10% fetal bovine serum. Transfections were performed as previously described (Tamura, M. and M. Noda., 1994), using a BBS calcium chloride precipitation. Forty-eight hours after transfection, the cells were harvested and assayed for luciferase and lacZ. Construction of the expression vectors pCS2-hND1 and pCS2-hND2 were as described in Example 10. The pGAP43-luc construct, a neuronal specific promoter construct that is upregulated *in vivo* in post-mitotic, terminally differentiating neurons (Nedivi et al., *J. Neurosci.* 12:691-704, 1992), contained the *GAP43* 760 base pair promoter region driving luciferase in a pGL2 vector modified to contain a poly-A site upstream of the multiple cloning site, and was the generous gift of Pate Skene and Joseph Weber. The pND2-luciferase construct was made by cloning a 1kb fragment of mouse *neuroD2* sequence terminating in the first exon, cloning this fragment into the pGL3 luciferase vector. The p4RTK-luciferase construct was made by placing the 4RTK region from HindIII to XhoI of the p4RTK-CAT vector (Weintraub et al., *Proc. Natl. Acad. Sci.* 87:5623-5627, 1990) into the promoterless luciferase vector. Luciferase assays were

performed according to Current Protocols in Molecular Biology (Brasier, A. R., John Wiley & Sons, New York, 1989).

When P19 cells were transfected as described above, it was observed that cotransfection with either pCS2-ND1 or pCS2-ND2 modestly increased the level of activity from p4RTK-luc in P19 cells, increasing the activity between two and four-fold.

Additional reporter constructs were tested in P19 cells to determine whether the *neuroD* and *neuroD2* proteins had different transcriptional activation potentials. Tests were conducted to determine the ability of pCS2-ND1 and pCS2-ND2 to transactivate the luciferase reporter construct, pGAP43-luciferase. In contrast to the simple E-box driven reporter, pCS2-ND1 did not show significant transactivation of the pGAP43-luciferase, while pCS2-ND2 induced expression from this construct by approximately 4-fold over the basal activity.

The myogenic bHLH proteins show auto- and cross-regulation, and expression of *NEX-1/MATH-2* has been shown to activate a reporter driven by the *NEX-1/MATH-2* promoter (Bartholoma and Nave, 1994). To determine if *neuroD1* or *neuroD2* could activate a construct containing the *neuroD2* promoter, we made a construct that contained a one kilobase fragment upstream of the mouse *neuroD2* gene, terminating in the first exon, driving the luciferase reporter gene. P19 cells were co-transfected with this pND2-luc reporter construct and the *neuroD* expression vectors. Both pCS2-ND1 and pCS2-ND2 transactivated this reporter construct, suggesting that *neuroD2* may be auto-regulated and cross-regulated by other members of the *neuroD* family, in a manner analogous to the regulation of the myogenic bHLH genes.

Together these transfection experiments demonstrate that *neuroD1* and *neuroD2* proteins can both activate some target genes, such as a multimerized E-box reporter and the *neuroD2* promoter; whereas the reporter construct driven by the *GAP43* promoter seems to be preferentially activated by *neuroD2*. At this time the amount of protein made from each vector following transfection cannot be quantitated, and interpretations rely on the relative activity of the reporter constructs. Further analysis of the specificity of *neuroD* and *neuroD2* will require identifying specific cis acting sequences in these reporters that mediate activity.

EXAMPLE 16

In situ localization of *neuroD1* and *neuroD2* RNA in adult mouse brain

To address the question of whether *neuroD1* and *neuroD2* were expressed in neurons in the adult mouse brain and whether they were expressed in the same cells, *in situ* hybridizations were performed using ³⁵S-UTP labeled RNA probes. Sections of adult mouse brain were hybridized to anti-sense probes derived from the mouse *neuroD1* and *neuroD2* cDNA fragments using T3 and T7 generated transcripts for sense and anti-sense probes, and incorporating ³⁵S-UTP label. Frozen 4-5 micron sagittal sections of adult mouse brain were cut, placed on Fisher Superfrost slides, and frozen at -80°C. Hybridization to ³⁵SUTP labeled probes and autoradiography was performed according to Masters et al. (*J. Neurosci.* 14:5844-5857, 1994), which is hereby incorporated by reference. After washing to remove unhybridized probe, sections were coated with liquid photographic emulsion. After development of the emulsion, dark field optics illuminated the silver grains as white spots at magnification X160.

In the cerebellum, *neuroD1* was easily detected in the granule layer, whereas the *neuroD2* signal was less intense in this region and was largely restricted to the region of the Purkinje cells. In contrast, the *neuroD1* and *neuroD2* signals in the pyramidal cells and dentate gyrus of the hippocampus were easily detected. The *neuroD2* probe hybridized preferentially to the region of the Purkinje cell layer. These results demonstrate that *neuroD1* and *neuroD2* are expressed in neuronal populations in the mature nervous system, and that their relative level of expression varies among neuronal populations.

From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modification may be made without deviating from the spirit and scope of the invention.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANTS: Weintraub, Harold M.
Lee, Jacqueline E.
Tapscott, Stephen J.
Hollenberg, Stanley M.
- (ii) TITLE OF INVENTION: Neurogenic Differentiation (NeuroD) Genes
and Proteins
- (iii) NUMBER OF SEQUENCES: 22
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Christensen O'Connor Johnson Kindness PLLC
 - (B) STREET: 1420 Fifth Avenue, Suite 2800
 - (C) CITY: Seattle
 - (D) STATE: WA
 - (E) COUNTRY: USA
 - (F) ZIP: 98101-2347
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER: US
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (vii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: US 08/239,238
 - (B) FILING DATE: 06-MAY-1994
- (viii) PRIOR APPLICATION DATA:
 - (A) APPLICATION NUMBER: WO PCT/US95/05741
 - (B) FILING DATE: 08-MAY-1995
- (ix) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Sheiness, Diana K.
 - (B) REGISTRATION NUMBER: 35,356
 - (C) REFERENCE/DOCKET NUMBER: FHCR-1-10112
- (x) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 206-224-0735
 - (B) TELEFAX: 206-225-0779

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 2089 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Mus musculus
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 229..1302
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACTACGCAGC ACCGAGGTAC AGACACGCCA GCATGAAGCA CTGCGTTTAA CTTTTCCTGG	60
AGGCATCCAT TTTGCAGTGG ACTCCTGTGT ATTTCTATTT GTGTGCATTT CTGTAGGATT	120
AGGGAGAGGG AGCTGAAGGC TTATCCAGCT TTAAATATA GCGGGTGGAT TTCCCCCCT	180
TTCTTCTTCT GCTTGCCTCT CTCCTGTTC AATACAGGAA GTGGAAAC ATG ACC AAA	237
Met Thr Lys	
1	
TCA TAC AGC GAG AGC GGG CTG ATG GGC GAG CCT CAG CCC CAA GGT CCC	285
Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro Gln Gly Pro	
5 10 15	
CCA AGC TGG ACA GAT GAG TGT CTC AGT TCT CAG GAC GAG GAA CAC GAG	333
Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu Glu His Glu	
20 25 30 35	
GCA GAC AAG AAA GAG GAC GAG CTT GAA GCC ATG AAT GCA GAG GAG GAC	381
Ala Asp Lys Lys Glu Asp Glu Leu Glu Ala Met Asn Ala Glu Glu Asp	
40 45 50	
TCT CTG AGA AAC GGG GGA GAG GAG GAG GAG GAA GAT GAG GAT CTA GAG	429
Ser Leu Arg Asn Gly Gly Glu Glu Glu Glu Glu Asp Glu Asp Leu Glu	
55 60 65	
GAA GAG GAG GAA GAA GAA GAG GAG GAG GAG GAT CAA AAG CCC AAG AGA	477
Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Gln Lys Pro Lys Arg	
70 75 80	
CGG GGT CCC AAA AAG AAA AAG ATG ACC AAG GCG CGC CTA GAA CGT TTT	525
Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu Glu Arg Phe	
85 90 95	
AAA TTA AGG CGC ATG AAG GCC AAC GCC CGC GAG CGG AAC CGC ATG CAC	573
Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn Arg Met His	
100 105 110 115	
GGG CTG AAC GCG GCG CTG GAC AAC CTG CGC AAG GTG GTA CCT TGC TAC	621
Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val Pro Cys Tyr	
120 125 130	
TCC AAG ACC CAG AAA CTG TCT AAA ATA GAG ACA CTG CGC TTG GCC AAG	669
Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg Leu Ala Lys	
135 140 145	
AAC TAC ATC TGG GCT CTG TCA GAG ATC CTG CGC TCA GGC AAA AGC CCT	717
Asn Tyr Ile Trp Ala Leu Ser Glu Ile Leu Arg Ser Gly Lys Ser Pro	
150 155 160	
GAT CTG GTC TCC TTC GTA CAG ACG CTC TGC AAA GGT TTG TCC CAG CCC	765
Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly Leu Ser Gln Pro	
165 170 175	
ACT ACC AAT TTG GTC GCC GGC TGC CTG CAG CTC AAC CCT CGG ACT TTC	813
Thr Thr Asn Leu Val Ala Gly Cys Leu Gln Leu Asn Pro Arg Thr Phe	
180 185 190 195	

TTG CCT GAG CAG AAC CCG GAC ATG CCC CCG CAT CTG CCA ACC GCC AGC Leu Pro Glu Gln Asn Pro Asp Met Pro Pro His Leu Pro Thr Ala Ser 200 205 210	861
GCT TCC TTC CCG GTG CAT CCC TAC TCC TAC CAG TCC CCT GGA CTG CCC Ala Ser Phe Pro Val His Pro Tyr Ser Tyr Gln Ser Pro Gly Leu Pro 215 220 225	909
AGC CCG CCC TAC GGC ACC ATG GAC AGC TCC CAC GTC TTC CAC GTC AAG Ser Pro Pro Tyr Gly Thr Met Asp Ser Ser His Val Phe His Val Lys 230 235 240	957
CCG CCG CCA CAC GCC TAC AGC GCA GCT CTG GAG CCC TTC TTT GAA AGC Pro Pro Pro His Ala Tyr Ser Ala Ala Leu Glu Pro Phe Phe Glu Ser 245 250 255	1005
CCC CTA ACT GAC TGC ACC AGC CCT TCC TTT GAC GGA CCC CTC AGC CCG Pro Leu Thr Asp Cys Thr Ser Pro Ser Phe Asp Gly Pro Leu Ser Pro 260 265 270 275	1053
CCG CTC AGC ATC AAT GGC AAC TTC TCT TTC AAA CAC GAA CCA TCC GCC Pro Leu Ser Ile Asn Gly Asn Phe Ser Phe Lys His Glu Pro Ser Ala 280 285 290	1101
GAG TTT GAA AAA AAT TAT GCC TTT ACC ATG CAC TAC CCT GCA GCG ACG Glu Phe Glu Lys Asn Tyr Ala Phe Thr Met His Tyr Pro Ala Ala Thr 295 300 305	1149
CTG GCA GGG CCC CAA AGC CAC GGA TCA ATC TTC TCT TCC GGT GCC GCT Leu Ala Gly Pro Gln Ser His Gly Ser Ile Phe Ser Ser Gly Ala Ala 310 315 320	1197
GCC CCT CGC TGC GAG ATC CCC ATA GAC AAC ATT ATG TCT TTC GAT AGC Ala Pro Arg Cys Glu Ile Pro Ile Asp Asn Ile Met Ser Phe Asp Ser 325 330 335	1245
CAT TCG CAT CAT GAG CGA GTC ATG AGT GCC CAG CTT AAT GCC ATC TTT His Ser His His Glu Arg Val Met Ser Ala Gln Leu Asn Ala Ile Phe 340 345 350 355	1293
CAC GAT TAGAGGGCAC GTCAGTTTCA CTATTCCTGG GAAACGAATC CACTGTGCGT His Asp	1349
ACAGTGACTG TCCTGTTTAC AGAAGGCAGC CCTTTTGCTA AGATTGCTGC AAAGTGCAAA	1409
TACTCAAAGC TTCAAGTGAT ATATGTATTT ATTGTCGTTA CTGCCTTTGG AAGAAACAGG	1469
GGATCAAAGT TCCTGTTTAC CTTATGTATT GTTTTCTATA GCTCTTCTAT TTTAAAAATA	1529
ATAATACAGT AAAGTAAAAA AGAAAATGTG TACCACGAAT TTCGTGTAGC TGTATTCAGA	1589
TCGTATTAAT TATCTGATCG GGATAAAAAA AATCACAAGC AATAATTAGG ATCTATGCAA	1649
TTTTTAAACT AGTAATGGGC CAATTAAAT ATATATAAAT ATATATTTTT CAACCAGCAT	1709
TTTACTACCT GTGACCTTTC CCATGCTGAA TTATTTTGT GTGATTTTGT ACAGAATTTT	1769

TAATGACTTT TTATAACGTG GATTCCTAT TTTAAAACCA TGCAGCTTCA TCAATTTTTA 1829
TACATATCAG AAAAGTAGAA TTATATCTAA TTTATACAAA ATAATTTAAC TAATTTAAAC 1889
CAGCAGAAAA GTGCTTAGAA AGTTATTGCG TTGCCTTAGC ACTTCTTTCT TCTCTAATTG 1949
TAAAAAAGAA AAAAAAAAAA AAAAACTCG AGGGGGGGCC CGGTACCCAG CTTTGTGCC 2009
CTTTAGTGAG GGTTAATTGC GCGCTTGGCG TAATCATGGT CATAGCTGTT TCCTGTGTGA 2069
ATTGTTATCC GCTCACAATT 2089

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 357 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro
1 5 10 15
Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu
20 25 30
Glu His Glu Ala Asp Lys Lys Glu Asp Glu Leu Glu Ala Met Asn Ala
35 40 45
Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Glu Glu Asp Glu
50 55 60
Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Gln Lys
65 70 75 80
Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
85 90 95
Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
100 105 110
Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
115 120 125
Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
130 135 140
Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile Leu Arg Ser Gly
145 150 155 160
Lys Ser Pro Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly Leu
165 170 175
Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu Gln Leu Asn Pro
180 185 190
Arg Thr Phe Leu Pro Glu Gln Asn Pro Asp Met Pro Pro His Leu Pro
195 200 205

Thr Ala Ser Ala Ser Phe Pro Val His Pro Tyr Ser Tyr Gln Ser Pro
 210 215 220
 Gly Leu Pro Ser Pro Pro Tyr Gly Thr Met Asp Ser Ser His Val Phe
 225 230 235 240
 His Val Lys Pro Pro Pro His Ala Tyr Ser Ala Ala Leu Glu Pro Phe
 245 250 255
 Phe Glu Ser Pro Leu Thr Asp Cys Thr Ser Pro Ser Phe Asp Gly Pro
 260 265 270
 Leu Ser Pro Pro Leu Ser Ile Asn Gly Asn Phe Ser Phe Lys His Glu
 275 280 285
 Pro Ser Ala Glu Phe Glu Lys Asn Tyr Ala Phe Thr Met His Tyr Pro
 290 295 300
 Ala Ala Thr Leu Ala Gly Pro Gln Ser His Gly Ser Ile Phe Ser Ser
 305 310 315 320
 Gly Ala Ala Ala Pro Arg Cys Glu Ile Pro Ile Asp Asn Ile Met Ser
 325 330 335
 Phe Asp Ser His Ser His His Glu Arg Val Met Ser Ala Gln Leu Asn
 340 345 350
 Ala Ile Phe His Asp
 355

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1275 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Xenopus laevis*

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 25..1083

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

ATTTCCTTTC TCCAGATCTA AAAA ATG ACC AAA TCG TAT GGA GAG AAT GGG	51
Met Thr Lys Ser Tyr Gly Glu Asn Gly	
1 5	
CTG ATC CTG GCC GAG ACT CCG GGC TGC AGA GGA TGG GTG GAC GAA TGC	99
Leu Ile Leu Ala Glu Thr Pro Gly Cys Arg Gly Trp Val Asp Glu Cys	
10 15 20 25	
CTG AGT TCT CAG GAT GAA AAC GAT CTG GAG AAA AAG GAG GGA GAG TTG	147
Leu Ser Ser Gln Asp Glu Asn Asp Leu Glu Lys Lys Glu Gly Glu Leu	
30 35 40	

ATG AAA GAA GAC GAT GAA GAC TCA CTG AAT CAT CAC AAT GGA GAG GAG Met Lys Glu Asp Asp Glu Asp Ser Leu Asn His His Asn Gly Glu Glu 45 50 55	195
AAC GAG GAA GAG GAT GAA GGG GAT GAG GAG GAG GAG GAC GAT GAA GAT Asn Glu Glu Glu Asp Glu Gly Asp Glu Glu Glu Glu Asp Asp Glu Asp 60 65 70	243
GAT GAT GAG GAT GAC GAC CAG AAA CCC AAA AGG CGA GGA CCG AAA AAG Asp Asp Glu Asp Asp Asp Gln Lys Pro Lys Arg Arg Gly Pro Lys Lys 75 80 85	291
AAA AAA ATG ACG AAA GCC CGG GTG GAG CGA TTT AAA GTG AGA CGC ATG Lys Lys Met Thr Lys Ala Arg Val Glu Arg Phe Lys Val Arg Arg Met 90 95 100 105	339
AAG GCA AAC GCC AGG GAG AGG AAT CGC ATG CAC GGA CTC AAC GAT GCC Lys Ala Asn Ala Arg Glu Arg Asn Arg Met His Gly Leu Asn Asp Ala 110 115 120	387
CTG GAC AGT CTG CGC AAA GTT GTG CCC TGC TAC TCC AAA ACA CAA AAG Leu Asp Ser Leu Arg Lys Val Val Pro Cys Tyr Ser Lys Thr Gln Lys 125 130 135	435
TTG TCT AAG ATT GAA ACT CTG CGC CTG GCT AAG AAC TAC ATC TGG GCT Leu Ser Lys Ile Glu Thr Leu Arg Leu Ala Lys Asn Tyr Ile Trp Ala 140 145 150	483
CTT TCT GAG ATT TTA AGG TCC GGC AAA AGC CCA GAC CTG GTG TCC TTT Leu Ser Glu Ile Leu Arg Ser Gly Lys Ser Pro Asp Leu Val Ser Phe 155 160 165	531
GTA CAA ACT CTC TGC AAA GGT TTG TCG CAG CCC ACC ACC AAT CTA GTA Val Gln Thr Leu Cys Lys Gly Leu Ser Gln Pro Thr Thr Asn Leu Val 170 175 180 185	579
GCG GGG TGT CTG CAG CTG AAC CCC AGA ACT TTC CTT CCT GAG CAG AGT Ala Gly Cys Leu Gln Leu Asn Pro Arg Thr Phe Leu Pro Glu Gln Ser 190 195 200	627
CAG GAC ATC CAG TCG CAC ATG CAA ACA GCG AGC TCT TCC TTC CCT CTG Gln Asp Ile Gln Ser His Met Gln Thr Ala Ser Ser Ser Phe Pro Leu 205 210 215	675
CAG GGC TAT CCC TAT CAG TCC CCT GGT CTT CCC AGT CCC CCC TAT GGT Gln Gly Tyr Pro Tyr Gln Ser Pro Gly Leu Pro Ser Pro Pro Tyr Gly 220 225 230	723
ACC ATG GAC AGC TCC CAT GTA TTC CAC GTC AAG CCT CAC TCC TAT GGG Thr Met Asp Ser Ser His Val Phe His Val Lys Pro His Ser Tyr Gly 235 240 245	771
GCG GCC CTG GAG CCT TTC TTT GAC AGC AGC ACC GTC ACT GAG TGT ACC Ala Ala Leu Glu Pro Phe Phe Asp Ser Ser Thr Val Thr Glu Cys Thr 250 255 260 265	819

AGC CCG TCA TTC GAT GGT CCC CTG AGC CCA CCC CTT AGT GTT AAT GGG 867
 Ser Pro Ser Phe Asp Gly Pro Leu Ser Pro Pro Leu Ser Val Asn Gly
 270 275 280

AAC TTT ACT TTT AAA CAC GAG CAT TCG GAG TAT GAT AAA AAT TAC ACG 915
 Asn Phe Thr Phe Lys His Glu His Ser Glu Tyr Asp Lys Asn Tyr Thr
 285 290 295

TTC ACT ATG CAC TAT CCT GCA GCC ACT ATA TCC CAG GGC CAC GGA CCA 963
 Phe Thr Met His Tyr Pro Ala Ala Thr Ile Ser Gln Gly His Gly Pro
 300 305 310

TTG TTC TCC ACG GGG GGA CCA CGC TGT GAA ATC CCA ATA GAC ACC ATC 1011
 Leu Phe Ser Thr Gly Gly Pro Arg Cys Glu Ile Pro Ile Asp Thr Ile
 315 320 325

ATG TCC TAT GAC GGT CAC TCC CAC CAT GAA AGA GTC ATG AGT GCC CAG 1059
 Met Ser Tyr Asp Gly His Ser His His Glu Arg Val Met Ser Ala Gln
 330 335 340 345

CTA AAT GCC ATC TTT CAT GAT TAACCCTTGG AAGATCAAAA CAACTGACTG 1110
 Leu Asn Ala Ile Phe His Asp
 350

TGCATTGCCA GGACTGTCTT GTTTACCAAG GGCAGACACG TGGGTAGTAA AAGTGCAAAT 1170

CCCCCACTCT GGGGCTGTAA CAAACTTGAT CTTGTCTGCT CTTTAGATAT GGGGAAACCT 1230

AATGTATTAA TTCCACCTC CTTCCAATCG ACACTCCTTT AAATT 1275

(2) INFORMATION FOR SEQ ID NO:4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 352 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:

Met Thr Lys Ser Tyr Gly Glu Asn Gly Leu Ile Leu Ala Glu Thr Pro
 1 5 10 15

Gly Cys Arg Gly Trp Val Asp Glu Cys Leu Ser Ser Gln Asp Glu Asn
 20 25 30

Asp Leu Glu Lys Lys Glu Gly Glu Leu Met Lys Glu Asp Asp Glu Asp
 35 40 45

Ser Leu Asn His His Asn Gly Glu Glu Asn Glu Glu Asp Glu Gly
 50 55 60

Asp Glu Glu Glu Glu Asp Asp Glu Asp Asp Asp Glu Asp Asp Asp Gln
 65 70 75 80

Lys Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg
 85 90 95

Val Glu Arg Phe Lys Val Arg Arg Met Lys Ala Asn Ala Arg Glu Arg
 100 105 110

Asn Arg Met His Gly Leu Asn Asp Ala Leu Asp Ser Leu Arg Lys Val
 115 120 125
 Val Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu
 130 135 140
 Arg Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile Leu Arg Ser
 145 150 155 160
 Gly Lys Ser Pro Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly
 165 170 175
 Leu Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu Gln Leu Asn
 180 185 190
 Pro Arg Thr Phe Leu Pro Glu Gln Ser Gln Asp Ile Gln Ser His Met
 195 200 205
 Gln Thr Ala Ser Ser Ser Phe Pro Leu Gln Gly Tyr Pro Tyr Gln Ser
 210 215 220
 Pro Gly Leu Pro Ser Pro Pro Tyr Gly Thr Met Asp Ser Ser His Val
 225 230 235 240
 Phe His Val Lys Pro His Ser Tyr Gly Ala Ala Leu Glu Pro Phe Phe
 245 250 255
 Asp Ser Ser Thr Val Thr Glu Cys Thr Ser Pro Ser Phe Asp Gly Pro
 260 265 270
 Leu Ser Pro Pro Leu Ser Val Asn Gly Asn Phe Thr Phe Lys His Glu
 275 280 285
 His Ser Glu Tyr Asp Lys Asn Tyr Thr Phe Thr Met His Tyr Pro Ala
 290 295 300
 Ala Thr Ile Ser Gln Gly His Gly Pro Leu Phe Ser Thr Gly Gly Pro
 305 310 315 320
 Arg Cys Glu Ile Pro Ile Asp Thr Ile Met Ser Tyr Asp Gly His Ser
 325 330 335
 His His Glu Arg Val Met Ser Ala Gln Leu Asn Ala Ile Phe His Asp
 340 345 350

(2) INFORMATION FOR SEQ ID NO:5:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 7 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(v) FRAGMENT TYPE: internal

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:

Asn Ala Arg Glu Arg Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:6:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 7 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:

Asn Glu Arg Glu Arg Asn Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:7:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 5 amino acids
 - (B) TYPE: amino acid
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: peptide
- (v) FRAGMENT TYPE: internal
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:

Asn Ala Arg Glu Arg
 1 5

(2) INFORMATION FOR SEQ ID NO:8:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 524 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: 9F1
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 57..524
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8:

TTTTTCTGCT TTTCTTTCTG TTGCCTCTC CCTTGTTGAA TGTAGGAAAT CGAAAC	56
ATG ACC AAA TCG TAC AGC GAG AGT GGG CTG ATG GGC GAG CCT CAG CCC	104
Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro	
1 5 10 15	
CAA GGT CCT CCA AGC TGG ACA GAC GAG TGT CTC AGT TCT CAG GAC GAG	152
Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu	
20 25 30	
GAG CAC GAG GCA GAC AAG AAG GAG GAC GAC CTC GAA GCC ATG AAC GCA	200
Glu His Glu Ala Asp Lys Lys Glu Asp Asp Leu Glu Ala Met Asn Ala	
35 40 45	
GAG GAG GAC TCA CTG AGG AAC GGG GGA GAG GAG GAG GAC GAA GAT GAG	248
Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Asp Glu Asp Glu	
50 55 60	

GAC CTG GAA GAG GAG GAA GAA GAG GAA GAG GAG GAT GAC GAT CAA AAG 296
 Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Asp Gln Lys
 65 70 75 80

CCC AAG AGA CGC GGC CCC AAA AAG AAG AAG ATG ACT AAG GCT CGC CTG 344
 Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
 85 90 95

GAG CGT TTT AAA TTG AGA CGC ATG AAG GCT AAC GCC CGG GAG CGG AAC 392
 Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
 100 105 110

CGC ATG CAC GGA CTG AAC GCG GCG CTA GAC AAC CTG CGC AAG GTG GTG 440
 Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
 115 120 125

CCT TGC TAT TCT AAG ACG CAG AAG CTG TCC AAA ATC GAG ACT CTG CGC 488
 Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
 130 135 140

TTG GCC AAG AAC TAC ATC TGG GCT CTG TCG GAG ATC 524
 Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile
 145 150 155

(2) INFORMATION FOR SEQ ID NO:9:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 156 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:9:

Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro
 1 5 10 15

Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu
 20 25 30

Glu His Glu Ala Asp Lys Lys Glu Asp Asp Leu Glu Ala Met Asn Ala
 35 40 45

Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Asp Glu Asp Glu
 50 55 60

Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Asp Gln Lys
 65 70 75 80

Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
 85 90 95

Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
 100 105 110

Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
 115 120 125

Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
 130 135 140

Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile
 145 150 155

(2) INFORMATION FOR SEQ ID NO:10:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1535 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: 14B1 (*neuroD2*)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 55..1194
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10:

```

CCCCTCACTT TGTGCTGTCT GTCTCCCCTT CCCGCCCGGG GNCCCTCAGG CACCATGCTG      60
ACCCGCCTGT TCAGCGAGCC CGGCCTTCTC TCGGACGTGC CCAAGTTCGC CAGCTGGGGC      120
GACGGCGAAG ACGACGAGCC GAGGAGCGAC AAGGGCGACG CGCCGCCACC GCCACCGCCT      180
GCGCCCGGGC CAGGGGCTCC GGGGCCAGCC CGGGCGGCCA AGCCAGTCCC TCTCCGTGGA      240
GAAGAGGGGA CGGAGGCCAC GTTGCCGAG GTCAAGGAGG AAGGCGAGCT GGGGGGAGAG      300
GAGGAGGAGG AAGAGGAGGA GGAAGAAGGA CTGGACGAGG CGGAGGGCGA GCGGCCCAAG      360
AAGCGCGGGC CCAAGAAGCG CAAGATGACC AAGGCGCGCT TGGAGCGCTC CAAGCTTCGG      420
CGGCAGAAGG CGAACGCGCG GGAGCGCAAC CGCATGCACG ACCTGAACGC AGCCCTGGAC      480
AACCTGCGCA AGGTGGTGCC CTGCTACTCC AAGACGAGA AGCTGTCCAA GATCGAGACG      540
CTGCGCCTAG CCAAGAACTA TATCTGGGCG CTCTCGGAGA TCCTGCGCTC CGGCAAGCGG      600
CCAGACCTAG TGTCTACGT GCAGACTCTG TGCAAGGGTC TGTCGCAGCC CACCACCAAT      660
CTGGTGCCCG GCTGTCTGCA GCTCAACTCT CGCAACTTCC TCACGGAGCA AGGCGCCGAC      720
GGTGCCGGCC GCTTCCACGG CTCGGGCGGC CCGTTCGCCA TGCACCCCTA CCCGTACCCG      780
TGCTCGCGCC TGGCGGGCGC ACAGTGCCAG GCGGCCGGCG GCCTGGGCGG CGGCGCGGCG      840
CACGCCCTGC GGACCCACGG CTA CTGCGGCC GCCTACGAGA CGCTGTATGC GGCGGCAGGC      900
GGTGGCGGCG CGAGCCCGGA CTACAACAGC TCCGAGTACG AGGGCCCGCT CAGCCCCCGG      960
CTCTGTCTCA ATGGCAACTT CTCACTCAAG CAGGACTCCT CGCCCGACCA CGAGAAAAGC     1020
TACCACTACT CTATGCACTA CTCGGCGCTG CCCGGTTCGC GCCACGGCCA CGGGCTAGTC     1080
TTGGCTCGT CGGCTGTGCG CGGGGGCGTC CACTCGGAGA ATCTTTGTC TTACGATATG     1140

```

CACCTTCACC ACGACCGGGG CCCCATGTAC GAGGAGCTCA ATGCGTTTTT TCATAACTGA 1200
 GACTTCGCGC CGNCTCCCTN CTTTTTCTTT TGCCTTTGCC CGCCCCCTG TCCCCAGCCC 1260
 CCAGAGCGCA GGGACACCCC CATNCTACCC CGGCNCCGGC GGAGCGGGCC ACCGGTCTGC 1320
 CGCTCTCCTG GGGCAGCGCA GTCTGTTACN TGTGGGTGGC TGTCCCAGGG GCCTCGCTTC 1380
 CCCCAGGGAC TCGCCTTCTC TCTCCAAGGG GTTCCCTCCT CCTCTCTCCC AAGGAGTGCT 1440
 TCTCCAGGGA CCTCTCTCCG GGGGCTCCCT GGAGGCACCC CTCCCCATT CCCAATATCT 1500
 TCGCTGAGGT TTCCTCCTCC CCCTCCTCCC TGCAG 1535

(2) INFORMATION FOR SEQ ID NO:11:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 381mino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:11:

Met Leu Thr Arg Leu Phe Ser Glu Pro Gly Leu Leu Ser Asp Val Pro
 1 5 10 15
 Lys Phe Ala Ser Trp Gly Asp Gly Glu Asp Asp Glu Pro Arg Ser Asp
 20 25 30
 Lys Gly Asp Ala Pro Pro Pro Pro Pro Ala Pro Gly Pro Gly Ala
 35 40 45
 Pro Gly Pro Ala Arg Ala Ala Lys Pro Val Pro Leu Arg Gly Glu Glu
 50 55 60
 Gly Thr Glu Ala Thr Leu Ala Glu Val Lys Glu Glu Gly Glu Leu Gly
 65 70 75 80
 Gly Glu Glu Glu Glu Glu Glu Glu Glu Glu Gly Leu Asp Glu Ala
 85 90 95
 Glu Gly Glu Arg Pro Lys Lys Arg Gly Pro Lys Lys Arg Lys Met Thr
 100 105 110
 Lys Ala Arg Leu Glu Arg Ser Lys Leu Arg Arg Gln Lys Ala Asn Ala
 115 120 125
 Arg Glu Arg Asn Arg Met His Asp Leu Asn Ala Ala Leu Asp Asn Leu
 130 135 140
 Arg Lys Val Val Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile
 145 150 155 160
 Glu Thr Leu Arg Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile
 165 170 175

Leu Arg Ser Gly Lys Arg Pro Asp Leu Val Ser Tyr Val Gln Thr Leu
 180 185 190
 Cys Lys Gly Leu Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu
 195 200 205
 Gln Leu Asn Ser Arg Asn Phe Leu Thr Glu Gln Gly Ala Asp Gly Ala
 210 215 220
 Gly Arg Phe His Gly Ser Gly Gly Pro Phe Ala Met His Pro Tyr Pro
 225 230 235 240
 Tyr Pro Cys Ser Arg Leu Ala Gly Ala Gln Cys Gln Ala Ala Gly Gly
 245 250 255
 Leu Gly Gly Gly Ala Ala His Ala Leu Arg Thr His Gly Tyr Cys Ala
 260 265 270
 Ala Tyr Glu Thr Leu Tyr Ala Ala Ala Gly Gly Gly Gly Ala Ser Pro
 275 280 285
 Asp Tyr Asn Ser Ser Glu Tyr Glu Gly Pro Leu Ser Pro Pro Leu Cys
 290 295 300
 Leu Asn Gly Asn Phe Ser Leu Lys Gln Asp Ser Ser Pro Asp His Glu
 305 310 315 320
 Lys Ser Tyr His Tyr Ser Met His Tyr Ser Ala Leu Pro Gly Ser Arg
 325 330 335
 His Gly His Gly Leu Val Phe Gly Ser Ser Ala Val Arg Gly Gly Val
 340 345 350
 His Ser Glu Asn Leu Leu Ser Tyr Asp Met His Leu His His Asp Arg
 355 360 365
 Gly Pro Met Tyr Glu Glu Leu Asn Ala Phe Phe His Asn
 370 375 380

(2) INFORMATION FOR SEQ ID NO:12:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1268 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: DNA (genomic)
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: 20A1 (neuroD3)
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 55..768
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12:

CTGCAGCGCT CTGAGCCGCT TTCTATCTGT CCGTCGGTCC TGCACAGCGC AACG ATG	57
Met	
1	
CCA GCC CGC CTT GAG ACC TGC ATC TCC GAC CTC GAC TGC GCC AGC AGC	105
Pro Ala Arg Leu Glu Thr Cys Ile Ser Asp Leu Asp Cys Ala Ser Ser	
5 10 15	
AGC GGC AGT GAC CTA TCC GGC TTC CTC ACC GAC GAG GAA GAC TGT GCC	153
Ser Gly Ser Asp Leu Ser Gly Phe Leu Thr Asp Glu Glu Asp Cys Ala	
20 25 30	
AGA CTC CAA CAG GCA GCC TCC GCT TCG GGG CCG CCC GCG CCG GCC CGC	201
Arg Leu Gln Gln Ala Ala Ser Ala Ser Gly Pro Pro Ala Pro Ala Arg	
35 40 45	
AGG GGC GCG CCC AAT ATC TCC CGG GCG TCT GAG GTT CCA GGG GCA CAG	249
Arg Gly Ala Pro Asn Ile Ser Arg Ala Ser Glu Val Pro Gly Ala Gln	
50 55 60 65	
GAC GAC GAG CAG GAG AGG CGG CGG CGC CGC GGC CGG ACG CGG GTC CGC	297
Asp Asp Glu Gln Glu Arg Arg Arg Arg Arg Gly Arg Thr Arg Val Arg	
70 75 80	
TCC GAG GCG CTG CTG CAC TCG CTG CGC AGG AGC CGG CGC GTC AAG GCC	345
Ser Glu Ala Leu Leu His Ser Leu Arg Arg Ser Arg Arg Val Lys Ala	
85 90 95	
AAC GAT CGC GAG CGC AAC CGC ATG CAC AAC TTG AAC GCG GCC CTG GAC	393
Asn Asp Arg Glu Arg Asn Arg Met His Asn Leu Asn Ala Ala Leu Asp	
100 105 110	
GCA CTG CGC AGC GTG CTG CCC TCG TTC CCC GAC GAC ACC AAG CTC ACC	441
Ala Leu Arg Ser Val Leu Pro Ser Phe Pro Asp Thr Lys Leu Thr	
115 120 125	
AAA ATC GAG ACG CTG CGC TTC GCC TAC AAC TAC ATC TGG GCT CTG GCC	489
Lys Ile Glu Thr Leu Arg Phe Ala Tyr Asn Tyr Ile Trp Ala Leu Ala	
130 135 140 145	
GAG ACA CTG CGC CTG GCG GAT CAA GGG CTG CCC GGA GGC GGT GCC CGG	537
Glu Thr Leu Arg Leu Ala Asp Gln Gly Leu Pro Gly Gly Gly Ala Arg	
150 155 160	
GAG CGC CTC CTG CCG CCG CAG TGC GTC CCC TGC CTG CCC GGT CCC CCA	585
Glu Arg Leu Leu Pro Pro Gln Cys Val Pro Cys Leu Pro Gly Pro Pro	
165 170 175	
AGC CCC GCC AGC GAC GCG GAG TCC TGG GGC TCA GGT GCC GCC GCC GCC	633
Ser Pro Ala Ser Asp Ala Glu Ser Trp Gly Ser Gly Ala Ala Ala Ala	
180 185 190	
TCC CCG CTC TCT GAC CCC AGT AGC CCA GCC GCC TCC GAA GAC TTC ACC	681
Ser Pro Leu Ser Asp Pro Ser Ser Pro Ala Ala Ser Glu Asp Phe Thr	
195 200 205	

TAC CGC CCC GGC GAC CCT GTT TTC TCC TTC CCA AGC CTG CCC AAA GAC 729
 Tyr Arg Pro Gly Asp Pro Val Phe Ser Phe Pro Ser Leu Pro Lys Asp
 210 215 220 225

TTG CTC CAC ACA ACG CCC TGT TTC ATT CCT TAC CAC TAGGCCCTTT 775
 Leu Leu His Thr Thr Pro Cys Phe Ile Pro Tyr His
 230 235

GTAGACACTG TTACTTTCCC CCTCCCCTAG TCAGCAGGCA ATAGATTGGG CCCAGCTGCC 835

GCCTCGGGAC CCCTCTCCAG GCGGAGGGAG GAAGCGGGAG CTTTAAAGCA GTCGGGGATA 895

CCTGAGCCGC TTGTTAGGTC GCCGCACCCT CGCGGCGGAT GTCTCTTGGT CTGTTTCTCC 955

GGCCCTCAGC CCAGCGCCCC TCCTGCCCCG CCCTAGACGG CCTTTCCTTT TGCACTTTCT 1015

GAAGTCCACA AAACCTCCTT TGTGACTGGC TCAGAACTGA CCCCAGCCAC CACTTCAGTG 1075

TGATTTAGAA AAGGGACAGA TCAGCCCCTG AAGACGAGGT GAAAAGTCAA TTTTACAATT 1135

TGTAGAACTC TAATGAAGAA AAACGAGCAT GAAAATTCGG TTTGAGCCGG CTGACAATAC 1195

AATGAAAAGG CTTAAAAAGC AGAGACAAGG AGTGGGCTTC ATGCATTATG GATCCCGACC 1255

CCCACCACTG CAG 1268

(2) INFORMATION FOR SEQ ID NO:13:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 237 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:13:

Met Pro Ala Arg Leu Glu Thr Cys Ile Ser Asp Leu Asp Cys Ala Ser
 1 5 10 15

Ser Ser Gly Ser Asp Leu Ser Gly Phe Leu Thr Asp Glu Glu Asp Cys
 20 25 30

Ala Arg Leu Gln Gln Ala Ala Ser Ala Ser Gly Pro Pro Ala Pro Ala
 35 40 45

Arg Arg Gly Ala Pro Asn Ile Ser Arg Ala Ser Glu Val Pro Gly Ala
 50 55 60

Gln Asp Asp Glu Gln Glu Arg Arg Arg Arg Arg Gly Arg Thr Arg Val
 65 70 75 80

Arg Ser Glu Ala Leu Leu His Ser Leu Arg Arg Ser Arg Arg Val Lys
 85 90 95

Ala Asn Asp Arg Glu Arg Asn Arg Met His Asn Leu Asn Ala Ala Leu
 100 105 110

Asp Ala Leu Arg Ser Val Leu Pro Ser Phe Pro Asp Asp Thr Lys Leu
 115 120 125

Thr Lys Ile Glu Thr Leu Arg Phe Ala Tyr Asn Tyr Ile Trp Ala Leu
 130 135 140
 Ala Glu Thr Leu Arg Leu Ala Asp Gln Gly Leu Pro Gly Gly Gly Ala
 145 150 155 160
 Arg Glu Arg Leu Leu Pro Pro Gln Cys Val Pro Cys Leu Pro Gly Pro
 165 170 175
 Pro Ser Pro Ala Ser Asp Ala Glu Ser Trp Gly Ser Gly Ala Ala Ala
 180 185 190
 Ala Ser Pro Leu Ser Asp Pro Ser Ser Pro Ala Ala Ser Glu Asp Phe
 195 200 205
 Thr Tyr Arg Pro Gly Asp Pro Val Phe Ser Phe Pro Ser Leu Pro Lys
 210 215 220
 Asp Leu Leu His Thr Thr Pro Cys Phe Ile Pro Tyr His
 225 230 235

(2) INFORMATION FOR SEQ ID NO:14:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1560 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Homo sapiens
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: HC2A
- (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 57..1126
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14:

TTTTTCTGCT TTTCTTTCTG TTTGCCTCTC CTTGTTGAA TGTAGGAAAT CGAAACATGA	60
CCAAATCGTA CAGCGAGAGT GGGCTGATGG GCGAGCCTCA GCCCAAGGT CCTCCAAGCT	120
GGACAGACGA GTGTCTCAGT TCTCAGGACG AGGAGCACGA GGCAGACAAG AAGGAGGACG	180
ACCTCGAAGC CATGAACGCA GAGGAGGACT CACTGAGGAA CGGGGAGAG GAGGAGGACG	240
AAGATGAGGA CCTGGAAGAG GAGGAAGAAG AGGAAGAGGA GGATGACGAT CAAAAGCCCA	300
AGAGACGCGG CCCCAAAAG AAGAAGATGA CTAAGGCTCG CCTGGAGCGT TTAAATTGA	360
GACGCATGAA GGCTAACGCC CGGGAGCGGA ACCGCATGCA CGGACTGAAC GCGGCGCTAG	420
ACAACCTGCG CAAGGTGGTG CCTTGCTATT CTAAGACGCA GAAGCTGTCC AAAATCGAGA	480
CTCTGCGCTT GGCCAAGAAC TACATCTGGG CTCTGTCGGA GATCCTGCGC TCAGGCAAAA	540
GCCCAGACCT GGTCTCCTTC GTTCAGACGC TTTGCAAGGG CTTATCCCAA CCCACCACCA	600
ACCTGGTTGC GGGCTGCCTG CAACTCAATC CTCGGACTTT TCTGCCTGAG CAGAACCAGG	660

```

ACATGCCCC GCACCTGCCG ACGGCCAGCG CTTCTTCCC TGTACACCCC TACTCCTACC      720
AGTCGCCTGG GCTGCCCAGT CCGNCTTACG GTACCATGGA CAGCTCCCAT GTCTTCCACG      780
TTAAGCCTCC GCCGCACGCC TACAGCGCAG CGCTGGAGCC CTTCTTTGAA AGCCCTCTGA      840
CTGATTGCAC CAGCCCTTCC TTTGATGGAC CCCTCAGCCC GCCGCTCAGC ATCAATGGCA      900
ACTTCTCTTT CAAACACGAA CCGTCCGCCG AGTTTGAGAA AAATTATGCC TTTACCATGC      960
ACTATCCTGC AGCGACACTG GCAGGGGCCC AAAGCCACGG ATCAATCTTC TCAGGCACCG     1020
CTGCCCCTCG CTGCGAGATC CCCATAGACA ATATTATGTC CTTGATAGC CATTACATC     1080
ATGAGCGAGT CATGAGTGCC CAGCTCAATG CCATATTTCA TGATTAGAGG CACGCCAGTT     1140
TCACCATTTT CGGGAACGA ACCCACTGTG CTTACAGTGA CTGTCGTGTT TACAAAAGGC     1200
AGCCCTTTGG TACTACTGCT GCAAAGTGCA AATACTCCAA GCTTCAAGTG ATATATGTAT     1260
TTATTGTCAT TACTGCCTTT GGAAGAAACA GGGGATCAAA GTTCCTGTTC ACCTTATGTA     1320
TTATTTTCTA TAGACTCTTC TATTTTAAAA AATAAAAAAA TACAGTAAAG TTTAAAAAAT     1380
ACACCACGAA TTTGGTGTGG CTGTATTCAG ATCGTATTAA TTATCTGATC GGGATAACAA     1440
AATCACAAGC AATAATTAGG ATCTATGCAA TTTTTAAACT AGTAATGGGC CAATTAAAAT     1500
ATATATAAAT ATATATTTCA ACCAGCATTT TACTACTTGT TACCTCCCAT GCTGAATTAT     1560

```

(2) INFORMATION FOR SEQ ID NO:15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 356 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Homo sapiens

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:15:

```

Met Thr Lys Ser Tyr Ser Glu Ser Gly Leu Met Gly Glu Pro Gln Pro
1           5           10           15

Gln Gly Pro Pro Ser Trp Thr Asp Glu Cys Leu Ser Ser Gln Asp Glu
20           25           30

Glu His Glu Ala Asp Lys Lys Glu Asp Asp Leu Glu Ala Met Asn Ala
35           40           45

Glu Glu Asp Ser Leu Arg Asn Gly Gly Glu Glu Glu Asp Glu Asp Glu
50           55           60

Asp Leu Glu Glu Glu Glu Glu Glu Glu Glu Asp Asp Asp Gln Lys
65           70           75           80

Pro Lys Arg Arg Gly Pro Lys Lys Lys Lys Met Thr Lys Ala Arg Leu
85           90           95

```

Glu Arg Phe Lys Leu Arg Arg Met Lys Ala Asn Ala Arg Glu Arg Asn
 100 105 110
 Arg Met His Gly Leu Asn Ala Ala Leu Asp Asn Leu Arg Lys Val Val
 115 120 125
 Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys Ile Glu Thr Leu Arg
 130 135 140
 Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu Ile Leu Arg Ser Gly
 145 150 155 160
 Lys Ser Pro Asp Leu Val Ser Phe Val Gln Thr Leu Cys Lys Gly Leu
 165 170 175
 Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys Leu Gln Leu Asn Pro
 180 185 190
 Arg Thr Phe Leu Pro Glu Gln Asn Gln Asp Met Pro Pro His Leu Pro
 195 200 205
 Thr Ala Ser Ala Ser Phe Pro Val His Pro Tyr Ser Tyr Gln Ser Pro
 210 215 220
 Gly Leu Pro Ser Pro Xaa Tyr Gly Thr Met Asp Ser Ser His Val Phe
 225 230 235 240
 His Val Lys Pro Pro Pro His Ala Tyr Ser Ala Ala Leu Glu Pro Phe
 245 250 255
 Phe Glu Ser Pro Leu Thr Asp Cys Thr Ser Pro Ser Phe Asp Gly Pro
 260 265 270
 Leu Ser Pro Pro Leu Ser Ile Asn Gly Asn Phe Ser Phe Lys His Glu
 275 280 285
 Pro Ser Ala Glu Phe Glu Lys Asn Tyr Ala Phe Thr Met His Tyr Pro
 290 295 300
 Ala Ala Thr Leu Ala Gly Ala Gln Ser His Gly Ser Ile Phe Ser Gly
 305 310 315 320
 Thr Ala Ala Pro Arg Cys Glu Ile Pro Ile Asp Asn Ile Met Ser Phe
 325 330 335
 Asp Ser His Ser His His Glu Arg Val Met Ser Ala Gln Leu Asn Ala
 340 345 350
 Ile Phe His Asp
 355

(2) INFORMATION FOR SEQ ID NO:16:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1951 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

- (ii) MOLECULE TYPE: cDNA
(vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mus musculus*
(vii) IMMEDIATE SOURCE:
 (B) CLONE: 1.1.1 (*mouse neuroD2*)
(ix) FEATURE:
 (A) NAME/KEY: CDS
 (B) LOCATION: 230..1378
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:16:

```
GAATTCAAGC TAGAGGCTGG TACCCCGCCT GGTAGAGATG CCACACTCGC TCCGCGGCTC      60
GCATGGCGCT CTGAAGACGC CGGCGCCCGC GCCTTGAGGA ACCGCTGCCC CCGCTCCCTG      120
AAGATGGGGG AACAAAGAAA TAAGCGAGAA GATTCTCTTT CTCCCCCTC TCTCTCTTGC      180
CCCCTCCCCC CTCCCCTCCC CTCTCCCCTT GACTCCTCTC TGAGGCACCA TGCTGACCCG      240
CCTGTTTCAGC GAGCCCGGCC TCCTCTCGGA CGTGCCCAAG TTCGCCAGCT GGGGCGACGG      300
CGACGACGAC GAGCCGAGGA GCGACAAGGG CGACGCGCCG CCGCAGCCTT CTCCTGCTCC      360
CGGGTCGGGG GCTCCAGGAC CCGCCCGGGC GCCTAAGCCA GTGTCTCTTC GTGGAGGAGA      420
AGAGATCCCT GAACCCACGT TGGCTGAGGT CAAGGAGGAA GGAGAGCTGG GCGGCGAGGA      480
GGAGGAGGAA GAGGAGGAGG AGGAAGGACT GGACGAGGCG GAAGGCGAGC GGCCCAAGAA      540
GCGCGGGCCG AAGAAACGCA AGATGACCAA GGCGCGTCTG GAGCGCTCCA AGCTGCGGCG      600
ACAGAAGGCC AATGCGCGCG AGCGCAACCG CATGCACGAC CTGAACGCGG CTCTGGACAA      660
CCTGCGCAAG GTGGTCCCTT GCTACTCAA GACCCAGAAG CTGTCCAAGA TCGAGACCCT      720
GCGCCTGGCC AAGAACTACA TCTGGGCTCT CTCGGAGATC TTGCGCTCCG GGAAGCGGCC      780
GGATCTGGTG TCCTACGTGC AGACTCTGTG CAAGGGGCTG TCACAGCCCA CCACGAATCT      840
GGTGGCCGGC TGCCTGCAGT TAAACTCTCG TAACTTCCTC ACGGAGCAGG GCGCGGACGG      900
CGCCGGCCGC TTTCACGGCT CGGGTGGCCC GTTCGCCATG CATCCGTACC CATACCCGTG      960
CTCCCGCCTG GCAGGCGCAC AGTGTGAGG GGTGCGCGGC CTGGGCGGAG GCGCGGCGCA     1020
CGCCCTGCGG ACCCACGGCT ACTGCGCCGC CTACGAGACG CTGTACGCGG CGGCCGGTGG     1080
CGGCGGCGCT AGCCCGGACT ACAACAGCTC CGAGTACGAG GGTCCACTCA GTCCCCGCT      1140
CTGTCTCAAC GGCAACTTCT CGCTCAAGCA GGACTCGTCC CCCGATCAG AGAAGAGCTA     1200
CCACTACTCT ATGCACTACT CGGCGCTGCC CGGCTCACGC CACGGCCACG GGCTGGTCTT     1260
CGGCTCGTCG GCCGTGCGCG GGGGCGTCCA CTCCGAGAAT CTCTTGTCTT ACGATATGCA     1320
CCTTCACCAC GATCGGGGCC CCATGTACGA GGAGCTCAAC GCATTTTCC ATAAGTGA      1380
CCTCNCGCCG ACCCCTTCTT TTTCTTTGCC TTTGTCCGGC CCCTTAGCCC CAGCCCCANN     1440
```

AGCTCAGGGA GCTCCCACCG ACTCCAGAGC CGGGCNCCTCG NCNCGCCGCC GGTTCTGCAG 1500
 CTCTCCAGAG CGGCGTGCTC TCTTACCTGT GGGTGGCCCG TCCAGGGGC CTCGCTTGCC 1560
 TCTGGGGA CTGCCTTCTCT CTCTCCCCAG CGGCTTCCTC CTCCCTTCTC TCGTGGAGAG 1620
 CATCTCTNNN GATCTCCCGC CAGCCCTCCC AAGAGACTTC CTCCACATTC CCAAACCTGG 1680
 GTTTCTCTC CCCACCTCCA ACAGGCCAGA GGAGTTGGTA AGGGGTGCTG AGTCTCGGGA 1740
 TAGTGTCTCC CCACTTATAG TTACTTAAAC AAACAAACAG ACACAGAGCT TCCAGCNAAA 1800
 AGAGTTGGTA TCTCTTCCTT CTCGAAGANC ACCAGCCAGG AGCCCAACCG CCTTCACCCT 1860
 AACACNGAAT CTCNNGTTT TTTATTTTTT ATTTTGGTGG GAGGGGATGT GGATTGAGAG 1920
 GAAAGAGAGA GCCAAGCCAA TTTGTAACTA G 1951

(2) INFORMATION FOR SEQ ID NO:17:

(i) SEQUENCE CHARACTERISTICS:
 (A) LENGTH: 382 amino acids
 (B) TYPE: amino acid
 (D) TOPOLOGY: linear
 (ii) MOLECULE TYPE: protein
 (vi) ORIGINAL SOURCE:
 (A) ORGANISM: *Mus musculus*
 (vii) IMMEDIATE SOURCE:
 (B) CLONE: 1.1.1 (murine *neuroD2*)
 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17:

Met Leu Thr Arg Leu Phe Ser Glu Pro Gly Leu Leu Ser Asp Val Pro
 1 5 10 15
 Lys Phe Ala Ser Trp Gly Asp Gly Asp Asp Asp Glu Pro Arg Ser Asp
 20 25 30
 Lys Gly Asp Ala Pro Pro Gln Pro Ser Pro Ala Pro Gly Ser Gly Ala
 35 40 45
 Pro Gly Pro Ala Arg Ala Ala Lys Pro Val Ser Leu Arg Gly Gly Glu
 50 55 60
 Glu Ile Pro Glu Pro Thr Leu Ala Glu Val Lys Glu Glu Gly Glu Leu
 65 70 75 80
 Gly Gly Glu Glu Glu Glu Glu Glu Glu Glu Gly Leu Asp Glu
 85 90 95
 Ala Glu Gly Glu Arg Pro Lys Lys Arg Gly Pro Lys Lys Arg Lys Met
 100 105 110
 Thr Lys Ala Arg Leu Glu Arg Ser Lys Leu Arg Arg Gln Lys Ala Asn
 115 120 125
 Ala Arg Glu Arg Asn Arg Met His Asp Leu Asn Ala Ala Leu Asp Asn
 130 135 140

-71-

Leu Arg Lys Val Val Pro Cys Tyr Ser Lys Thr Gln Lys Leu Ser Lys
 145 150 155 160
 Ile Glu Thr Leu Arg Leu Ala Lys Asn Tyr Ile Trp Ala Leu Ser Glu
 165 170 175
 Ile Leu Arg Ser Gly Lys Arg Pro Asp Leu Val Ser Tyr Val Gln Thr
 180 185 190
 Leu Cys Lys Gly Leu Ser Gln Pro Thr Thr Asn Leu Val Ala Gly Cys
 195 200 205
 Leu Gln Leu Asn Ser Arg Asn Phe Leu Thr Glu Gln Gly Ala Asp Gly
 210 215 220
 Ala Gly Arg Phe His Gly Ser Gly Gly Pro Phe Ala Met His Pro Tyr
 225 230 235 240
 Pro Tyr Pro Cys Ser Arg Leu Ala Gly Ala Gln Cys Gln Ala Ala Gly
 245 250 255
 Gly Leu Gly Gly Gly Ala Ala His Ala Leu Arg Thr His Gly Tyr Cys
 260 265 270
 Ala Ala Tyr Glu Thr Leu Tyr Ala Ala Ala Gly Gly Gly Gly Ala Ser
 275 280 285
 Pro Asp Tyr Asn Ser Ser Glu Tyr Glu Gly Pro Leu Ser Pro Pro Leu
 290 295 300
 Cys Leu Asn Gly Asn Phe Ser Leu Lys Gln Asp Ser Ser Pro Asp His
 305 310 315 320
 Glu Lys Ser Tyr His Tyr Ser Met His Tyr Ser Ala Leu Pro Gly Ser
 325 330 335
 Arg His Gly His Gly Leu Val Phe Gly Ser Ser Ala Val Arg Gly Gly
 340 345 350
 Val His Ser Glu Asn Leu Leu Ser Tyr Asp Met His Leu His His Asp
 355 360 365
 Arg Gly Pro Met Tyr Glu Glu Leu Asn Ala Phe Phe His Asn
 370 375 380

(2) INFORMATION FOR SEQ ID NO:18:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 20 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA
- (vii) IMMEDIATE SOURCE:
 - (B) CLONE: JL34
- (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18:

CTCAGCATCA GCAACTCGGC

- (2) INFORMATION FOR SEQ ID NO:19:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 29 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (vii) IMMEDIATE SOURCE:
 - (B) CLONE: JL36
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19:

TCGGATCCCG TTCTAGGCGC GCCTTGTC

29

- (2) INFORMATION FOR SEQ ID NO:20:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 21 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: single
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: cDNA
 - (vii) IMMEDIATE SOURCE:
 - (B) CLONE: JL40
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20:

GTTTCCCGAG TCACGACGTT G

21

- (2) INFORMATION FOR SEQ ID NO:21:
- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 1333 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
 - (ii) MOLECULE TYPE: DNA (genomic)
 - (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Mus musculus
 - (vii) IMMEDIATE SOURCE:
 - (B) CLONE: neuroD3
 - (ix) FEATURE:
 - (A) NAME/KEY: CDS
 - (B) LOCATION: 101..835
 - (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21:

CTGCAGAGGA CAGGTAGCCC CGGGTCGTAC GGACAGTAAG TGCCTTCGA AGGCCGACCT

60

CCAAACCTCC TGTCCGTCTG TCGGTCCTGC ACACTGCAAG ATG CCT GCC CCT TTG
Met Pro Ala Pro Leu
1 5

115

GAG ACC TGC ATC TCT GAT CTC GAC TGC TCC AGC AGC AAC AGC AGC AGC
Glu Thr Cys Ile Ser Asp Leu Asp Cys Ser Ser Ser Asn Ser Ser Ser
10 15 20

163

GAC CTG TCC AGC TTC CTC ACC GAC GAG GAG GAC TGT GCC AGG CTA CAG
Asp Leu Ser Ser Phe Leu Thr Asp Glu Glu Asp Cys Ala Arg Leu Gln
25 30 35

211

CCC CTA GCC TCC ACC TCG GGG CTG TCC GTG CCA GCC CGG AGG AGC GCT	259
Pro Leu Ala Ser Thr Ser Gly Leu Ser Val Pro Ala Arg Arg Ser Ala	
40 45 50	
CCC GCC CTC TCC GGG GCA TCG AAT GTT CCC GGT GCC CAG GAC GAA GAG	307
Pro Ala Leu Ser Gly Ala Ser Asn Val Pro Gly Ala Gln Asp Glu Glu	
55 60 65	
CAG GAA CGG CGG AGG CGG CGA GGT CGC GCT CGG GTG CGG TCC GAG GCT	355
Gln Glu Arg Arg Arg Arg Gly Arg Ala Arg Val Arg Ser Glu Ala	
70 75 80 85	
CTG CTG CAC TCC CTG CGG AGG AGT CGT CGC GTC AAA GCC AAC GAT CGC	403
Leu Leu His Ser Leu Arg Arg Ser Arg Arg Val Lys Ala Asn Asp Arg	
90 95 100	
GAG CGC AAC CGC ATG CAC AAC CTC AAC GCT GCG CTG GAC GCC TTG CGC	451
Glu Arg Asn Arg Met His Asn Leu Asn Ala Ala Leu Asp Ala Leu Arg	
105 110 115	
AGC GTG CTG CCC TCG TTC CCC GAC GAC ACC AAG CTC ACC AAG ATT GAG	499
Ser Val Leu Pro Ser Phe Pro Asp Asp Thr Lys Leu Thr Lys Ile Glu	
120 125 130	
ACG CTG CGC TTC GCC TAC AAC TAC ATC TGG GCC CTG GCT GAG ACA CTG	547
Thr Leu Arg Phe Ala Tyr Asn Tyr Ile Trp Ala Leu Ala Glu Thr Leu	
135 140 145	
CGC CTG GCA GAT CAA GGG CTC CCC GGG GGC AGT GCC CGG GAG CGC CTC	595
Arg Leu Ala Asp Gln Gly Leu Pro Gly Gly Ser Ala Arg Glu Arg Leu	
150 155 160 165	
CTG CCT CCG CAG TGT GTC CCC TGT CTG CCC GGG CCC CCG AGC CCG GCC	643
Leu Pro Pro Gln Cys Val Pro Cys Leu Pro Gly Pro Pro Ser Pro Ala	
170 175 180	
AGC GAC ACT GAG TCC TGG GGT TCC GGG GCC GCT GCC TCC CCC TGC GCC	691
Ser Asp Thr Glu Ser Trp Gly Ser Gly Ala Ala Ala Ser Pro Cys Ala	
185 190 195	
ACT GTG GCA TCA CCA CTC TCT GAC CCC AGT AGT CCC TCG GCT TCA GAA	739
Thr Val Ala Ser Pro Leu Ser Asp Pro Ser Ser Pro Ser Ala Ser Glu	
200 205 210	
GAC TTC ACC TAT GGC CCG GGC GAT CCC CTT TTC TCC TTT CCT GGC CTG	787
Asp Phe Thr Tyr Gly Pro Gly Asp Pro Leu Phe Ser Phe Pro Gly Leu	
215 220 225	
CCC AAA GAC CTG CTC CAC ACG ACG CCC TGT TTC ATC CCA TAC CAC TAGGCCTTTG	
842	
Pro Lys Asp Leu Leu His Thr Thr Pro Cys Phe Ile Pro Tyr His	
230 235 240 245	
TAAGGCAACA TCAATACATT CTCCTCCCC CAGTCTAAGA GCAATAATAG ATGGGGAAC	902
GGCTGAAGCC TCCGGGGGCC ACACTTACCC CCAAGTGAAT TCTGGGAGCT TTAAAGGGG	962
GAGGGGGAAT ACCTGACCAC TTGTTAGGTT GCTGCACCCT CGCTGAAGCT GCCCTCGGTC	1022

TATTTCTCCA CCCCCAGCAC GGCCTCCCCC CCCCCCGCCC GCCCCCAGAC GGCCTTTCGT 1082
 TTTTGTGCA CTTTCTGAAC TTCACAAAAC CTTCTTTGTG ACTGGCTCAG AACTGACCCC 1142
 AGCCACCACT TCAGTGTGGT TTGGAAAAGG GACAGATGAG CCCCTGAAGA CGAGGTGAAA 1202
 AGTCAATTTT ACAATTTGTA GAACTCTAAT GAAGAAAAAC GAGCATGAAA ATTCGGTTTG 1262
 AGCCGGCTGA CAATACAATG GCAAGGCTTA AAAAGGAGCC ACAAGGAGTG GGCTTCATGC 1322
 ATTATGGATC C 1333

(2) INFORMATION FOR SEQ ID NO:22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 244 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:22:

Met Pro Ala Pro Leu Glu Thr Cys Ile Ser Asp Leu Asp Cys Ser Ser
 1 5 10 15
 Ser Asn Ser Ser Ser Asp Leu Ser Ser Phe Leu Thr Asp Glu Glu Asp
 20 25 30
 Cys Ala Arg Leu Gln Pro Leu Ala Ser Thr Ser Gly Leu Ser Val Pro
 35 40 45
 Ala Arg Arg Ser Ala Pro Ala Leu Ser Gly Ala Ser Asn Val Pro Gly
 50 55 60
 Ala Gln Asp Glu Glu Gln Glu Arg Arg Arg Arg Gly Arg Ala Arg
 65 70 75 80
 Val Arg Ser Glu Ala Leu Leu His Ser Leu Arg Arg Ser Arg Arg Val
 85 90 95
 Lys Ala Asn Asp Arg Glu Arg Asn Arg Met His Asn Leu Asn Ala Ala
 100 105 110
 Leu Asp Ala Leu Arg Ser Val Leu Pro Ser Phe Pro Asp Asp Thr Lys
 115 120 125
 Leu Thr Lys Ile Glu Thr Leu Arg Phe Ala Tyr Asn Tyr Ile Trp Ala
 130 135 140
 Leu Ala Glu Thr Leu Arg Leu Ala Asp Gln Gly Leu Pro Gly Gly Ser
 145 150 155 160
 Ala Arg Glu Arg Leu Leu Pro Pro Gln Cys Val Pro Cys Leu Pro Gly
 165 170 175
 Pro Pro Ser Pro Ala Ser Asp Thr Glu Ser Trp Gly Ser Gly Ala Ala
 180 185 190

Ala Ser Pro Cys Ala Thr Val Ala Ser Pro Leu Ser Asp Pro Ser Ser
195 200 205

Pro Ser Ala Ser Glu Asp Phe Thr Tyr Gly Pro Gly Asp Pro Leu Phe
210 215 220

Ser Phe Pro Gly Leu Pro Lys Asp Leu Leu His Thr Thr Pro Cys Phe
225 230 235 240

Ile Pro Tyr His

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. An isolated polynucleotide molecule that encodes a *neuroD* polypeptide and that hybridizes under stringent conditions with a nucleic acid molecule selected from among SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:21, or its complement.
2. The isolated polynucleotide molecule of Claim 1, said polynucleotide molecule encoding a human *neuroD2* polypeptide, and further being capable of hybridizing under stringent conditions with the nucleotide sequence of SEQ ID NO:10, or its complement.
3. The isolated polynucleotide molecule of Claim 1, said polynucleotide molecule encoding a human *neuroD3* polypeptide, and further being capable of hybridizing under stringent conditions with the nucleotide sequence of SEQ ID NO:12, or its complement.
4. An isolated polynucleotide molecule that comprises at least 15 nucleotides and that hybridizes under stringent conditions with a *neuroD* HLH domain selected from among nucleotides 577-696 of SEQ ID NO:1, nucleotides 376-495 of SEQ ID NO:3, nucleotides 149-268 of SEQ ID NO:8, nucleotides 463-582 of SEQ ID NO:10, nucleotides 368-496 of SEQ ID NO:12, nucleotides 405-524 of SEQ ID NO:14, nucleotides 642-761 of SEQ ID NO:16, nucleotides 425-544 of SEQ ID NO:21, or its complement.
5. A vector comprising the following operably linked elements: a promoter, the polynucleotide molecule of Claim 1, and a transcription termination signal.
6. A cell transformed by the polynucleotide molecule of Claim 1.
7. A recombinant peptide encoded by the polynucleotide molecule of Claim 1.
8. An antibody or antigen-binding fragment thereof that binds to the recombinant peptide of Claim 9.

9. An antibody or antigen-binding fragment thereof that binds to a polypeptide selected from among SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:9, SEQ ID NO:11, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:17, and SEQ ID NO:22.

10. An antibody or antigen-binding fragment thereof that binds to a peptide selected from among amino acid residues 117-156 of SEQ ID NO:2, amino acid residues 118-157 of SEQ ID NO:4, amino acid residues 117-156 of SEQ ID NO:9, amino acid residues of 137-176 of SEQ ID NO:11, amino acid residues 108-147 of SEQ ID NO. 13, amino acid residues 117-156 of SEQ ID NO:15, amino acid residues 138-177 of SEQ ID NO:17, and amino acid residues 109-148 of SEQ ID NO:22.




Figure 1

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/17532

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12N 15/12, 15/85; A61K 39/395; C07K 14/48

US CL : 435/69.1, 172.3, 240.2, 320.1; 536/23.1, 23.5; 530/350, 387.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/69.1, 172.3, 240.2, 320.1; 536/23.1, 23.5; 530/350, 387.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, DIALOG: CAS, MEDLINE, BIOSIS, Derwent Biotechnology Abstracts

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Gobel et al. NSCL-2: A basic domain helix-loop-helix gene expressed in early neurogenesis. Cell Growth and Differentiation. March 1992. Vol. 3 pages 143-148, see entire document.	1-10

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principles or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	X*	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	Y*	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may show doubts as to priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	Δ*	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 JANUARY 1997

Date of mailing of the international search report

05 FEB 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer

JOHN LEGUYADER

Facsimile No. (703) 305-3230

Telephone No. (703) 308-0196